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ABSTRACT 
 
Kaiulani Michelle Houston: Development of Protease-Resistant β-Hairpin Peptides for 
the Detection of Enzymatic Activity in Cancer Cells 
(Under the direction of Marcey L. Waters) 
 
Multiple myeloma (MM) is an incurable malignancy of the antibody-producing 
plasma cells in the bone marrow and is characterized by the targeted degradation of anti-
tumor regulatory proteins by the ubiquitin proteasome system (UPS). The development of 
proteasomal inhibitors, such as bortezomib (Velcade®), has greatly improved the median 
survival time of MM patients. Inappropriate activation of protein kinase B (PKB or Akt) 
by bortezomib has been observed leading to refractory disease. Inhibitors of PKB activity 
are now in clinical trials for the treatment of MM.  Chronic myelogenous leukemia 
(CML), the malignancy of myeloid cells in the bone marrow, is treated predominantly 
with Abl kinase inhibitors. We have designed protease-resistant fluorescent peptide 
probes that, once optimized, can be used to determine the effectiveness of these inhibitors 
by direct measurement of proteasomal and Abl kinase hyperactivity and PKB activation 
in patient cells.  
Measuring intracellular UPS and kinase activity through the use of unstructured 
synthetic peptide substrates is limited by the vulnerability of these substrates to rapid 
degradation in the cell by cytosolic proteases.    Unstructured peptides in the cytosol of 
immune cells are threaded into protease active sites at the N-terminus. 
We designed and synthesized short, well-folded protease resistant β-hairpin peptides 
through the incorporation of favorable cross-strand side chain interactions and a 
stabilizing turn nucleating sequence. Designing the β-hairpins to include ornithine, a 
noncanonical amino acid analog of lysine, and D-amino acids, produced long-lived 
peptides with half-lives of 2-6 hours and non-degradable peptides, in the presence of 
specific and nonspecific proteases in vitro.  These β-hairpin peptides were covalently 
attached to the N-terminus of unstructured kinase substrate peptides resulting in increased 
stability to peptidases in vitro while maintaining efficacy as kinase substrates.   
Here we also show that short β-hairpin peptides, not derived from natural protein 
targets, adequately served as substrates of the UPS.  We demonstrated that ornithine can 
be ubiquitinated by UPS enzymes regardless of secondary structure in a site-specific 
manner.  Finally we show the applicability of these hairpin degrons in determining UPS 
activity in diseases such as MM, where UPS inhibitors are part of mainline and emerging 
treatments. 
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Chapter I 
 
PEPTIDES USED TO MONITOR ENZYMATIC ACTIVITY 
 
A. Introduction 
 
During the 20th and early 21st centuries, clinical diagnosis and treatment went from 
being predominantly macroscopic to being mostly microscopic.  Nearly every medical 
diagnosis in well-developed countries is validated by one or more molecular tests that 
screen for a microscopic indication of disease.1    The development and advancement of 
microscopy, spectroscopy, antibody-based assays, and the mapping of the human genome 
and proteome, has allowed for an increased understanding of disease causation and the 
determination of the mechanisms of action of drugs on their molecular targets.  
Knowledge of pharmaceutical targets and drug modes of action has led to the 
development of ways to monitor disease progression and remission at the molecular 
level.2 Clinicians and bench scientists are designing ways to directly and molecularly 
measure the effects of therapeutic agents on their molecular targets during the course of 
the treatment. 
________________________ 
1Yager, P.; Edwards, T.; Fu, E.; Helton, K.; Nelson, K.; Tam, M.R.; Weigl, B.H. 
Nature2006, 442, 412-18. 
 
2Hudis, C.A. N Engl J Med 2007, 357, 39-51. 
	   2	  
The treatment of multiple myeloma (MM), an incurable hematologic malignancy of 
the plasma cells in the bone marrow, has greatly advanced with the FDA approval of 
molecularly targeted therapeutics.3  However, none of the current diagnostic tests directly 
measure the activity of enzymes and protein-protein interactions targeted by these novel 
treatments.3     In this chapter, we will briefly discuss the current state of MM diagnostics 
and the ways in which the effectiveness of the molecularly-targeted therapeutics used to 
treat the disease can be measured during the course of treatment.  Specifically, we will 
highlight examples of how peptides can be used in the future to monitor disease 
progression and eventual remission by directly evaluating cytosolic enzymatic activity 
relevant to disease states.   We will conclude with our proposal to design and use 
fluorescent peptide-based probes for the monitoring of therapeutic agent effectiveness 
during MM treatment with enzyme inhibitors. 
B. Multiple myeloma diagnosis and treatment today 
Multiple myeloma (MM) is the monoclonal proliferation of plasma cells, the 
antibody-producing white blood cells present in the bone marrow, and accounts for 10% 
of all hematologic malignancies in the Unites States.4   MM arises from the accumulation 
of genetic errors in plasma cells that lead to constitutively active, hypoactive or 
dysregulated protein activity.5 
________________________ 
3Palumbo, A.; Anderson, K. N Engl J Med2011, 364, 1046-60. 
4Kyle, R.A.; Rajkuma, S.V. Blood2008, 111, 2962-72. 
5Ocio, E.M.; Mateos, M.V.; Maiso, P.; Pandiella, A.; San-Miguel, J.F. Lancet 
Oncol2008, 9,1157-65. 
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Currently, a MM diagnosis depends on the combined outcome of several tests including, 
serum immunoglobulin levels (the heavy chain of antibodies), light chain protein 
concentration in the urine, bone marrow plasma cell population density, and the 
karyotyping of the plasma cells in the bone marrow.3   High concentrations of bone 
marrow plasma cells and monoclonal antibodies, cytogenetic abnormalities within the 
nuclei of myeloma cells, and physical symptoms such as anemia and bone lesions 
constitutes a diagnosis.  Further investigation of chromosome abnormalities using 
fluorescence in situ hybridization (FISH), is done to determine the prognosis of the 
patient, with certain karyotypes associated a better outcome than others.  The high 
concentrations of proteins including beta2-microglobulin and M-protein in the serum and 
urine are associated with more advanced stage disease.3  Patients with a good immediate 
prognosis are first treated with an autologous stem cell transplant and then with a 
combination of chemotherapeutic agents targeting the catalytic activity of enzymes such 
as the 26S proteasome and histone deacetylases (HDACs), E3 ligase protein-protein 
interactions, and DNA replication.5   Though all patients with treatable MM are 
prescribed pharmaceutical drugs that target protein activity and interactions, none of the 
above mentioned diagnostic tests directly measure the activity targeted by the prescribed 
drugs.  As the knowledge of MM pathogenesis increases, the number of new potential 
drug targets also increases.   Many FDA approved drugs and novel therapeutics currently 
being investigated in clinical trials are inhibitors of intracellular enzymes in signal 
transduction pathways that have been usurped by inappropriately regulated oncogenes, 
and thus contribute to tumor cell survival.5   One such enzymatic signaling pathway is the 
ubiquitin-proteasome system (UPS), a family of nearly 1000 enzymes required for cell 
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homeostasis, namely through directing intracellular trafficking and protein degradation 
by the 26S proteasome.6  Since the FDA approval of the 26S proteasome inhibitor 
bortezomib (Velcade) in 2003, the overall median survival of patients with MM has 
lengthened from 2-3 years to 5-10+ years depending on age and cytogenetic factors.3,7  
Several next generation proteasome inhibitors have been developed and targeting the 
entire (UPS) for the treatment of several diseases in addition to MM, is projected in the 
next decade to become as popular as targeting kinase/phosphatase signaling, which 
dominates 25% percent of the drug market today.8 
Some clinical trials associated with inhibitors of kinases and UPS enzymes have 
failed in the late stages due to underwhelming effects on patient overall survival.9   MM 
patients enrolled the Stage II/III clinical trial for perifosine, an allosterictic inhibitor of 
protein kinase B (PKB or Akt) activity, were screened for cytogenetic abnormalities 
associated with improper immunoglobulin production and excretion, and for their status 
as relapsed/refractory in response to combination therapies including 
bortezomib/thalidomide (immunomodulatory agent)/lenolidomide. The patient tumor 
cell-associated PKB activity was not determined prior to enrollment.  Though aberrant 
PKB activity has been implicated in tumor growth presumably due to its roles in cellular 
metabolism, motility, proliferation, and angiogenesis, PKB may not be activated or 
hyperactive in all cancers.10   
_______________________ 
6Nandi, D.; Tahiliani, P.; Kumar, A.; Chandu, D. J Biosci2006, 31, 137-55. 
7Samson, D. Postgrad Med J 1994, 70, 404-10. 
8(a) Cohen, P.; Tcherpakov, M.; Cell2010, 143, 686-93 (b) Gonzalez-Vera, J.A. Chem 
Soc Rev2012, 41,1652-64. 
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Perifosine investigation was halted in Stage III though it showed synergistic activity with 
bortezomib.9-10  Though bortezomib has been shown to activate PKB in some MM 
tumors, it is not known whether or not the activity of PKB was dysregulated in all MM 
patient tumors investigated and therefore the inhibitor may be useful for only a subset of 
patients.11  Despite the short-term and long-term effectiveness of enzyme inhibitors in the 
treatment of MM, no diagnostic testing is associated with determining enzyme activity in 
biopsied myeloma cells.  This gap in diagnostic testing is due to the absence of high 
throughput assays that can detect enzymatic activity in a small number of cells.  As low 
as 10% of the bone marrow cells collected from patient biopsies must be plasma cells in 
order to constitute a possible malignant diagnosis.3  Many techniques that measure 
enzymatic expression and activity such as Western Blotting, immunocoprecipitation, and 
ELISA require one million cells for an accurate readout while MM biopsies can 
sometimes yield less than 1000 malignant cells. Chemical cytometry assessing enzymatic 
activity relevant to disease progression in patient tumor cells at diagnosis would give 
clinicians the information needed to personalize treatments for their patients. Assessing 
targeted enzymatic activity prior to clinical trial enrollment would allow investigators the 
ability to enroll patients based on their aberrant enzyme activity status and thus more 
accurately determine who would most benefit from treatment.   
________________________  
9Richardson, P.G.; Nagler, A.; Yehuda, D.B.; Badros, Hari, P.; Hajek, R.; Spicka, I.; 
Kaya, H.; Le Blanc, R.; Yoon, S.S.; Kim, K.; Martinez-Lopez, J.; Mittelman, M.; 
Shpilberg, O.; Tothova, E.; Laubach, J.P.; Ghobrial, I.M.; Leiba, M.; Gatt, M.E.; 
Sportelli, P.; Chen, M.; Anderson, K.C. Blood2013, 122, 3189. 
 
10 Richardson, P.G.; Eng, C.; Kolesar, J.; Hideshima, T.; Anderson, K.C. Expert Opin 
Drug Metab Toxicol 2012, 8, 623-33. 
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Another advantage of being able to directly measure enzymatic activity during 
treatment and/or clinical trial investigation of an enzyme inhibitor would be the ability to 
directly monitor the drug inhibitor’s effect on its targeted activity.  As in the case with 
MM where traditional treatment regiments include a combination of multiple enzyme 
inhibitors, a rapid high-throughput screening of several enzymes simultaneously would 
be ideal.   Another factor to take into consideration is tumor heterogeneity.  The 
enzymatic activity in tumor cells is not homogenous even when the tumor cells are all 
taken out of the same patient.12  Early detection of treatment-resistant tumor cell 
populations would allow clinicians to implement an alternative treatment plan long 
before indirect measurements of relapse become detectable.      
 Below we will highlight a few types fluorescent peptide-based probes developed 
by others that are capable of detecting enzymatic activity in vitro, in vivo, and ex vivo in 
just a single cell. Our primary focus is on the detection of kinase activity and UPS 
enzymatic activity as these are relevant drug targets for the treatment of MM. We will 
briefly discuss the major challenges of using peptide-based probes to assess enzymatic 
activity in the cytosol of cells and introduce our proposed method to overcome these 
challenges.  The use of the methods discussed is restricted mostly to bench research 
analysis rather than for a clinical testing.  We hope the work described in the remaining 
chapters will be a foundation for the translation of direct enzymatic activity assays from 
bench top experimentation only to clinical diagnostics and disease-monitoring 
technology. 
________________________ 
11Mahindra, A.; Laubach, J.; Raje, N.; Munshi, N.; Richardson, P.G., Anderson, K. Nat 
Rev Clin Oncol2012, 9, 135-43. 
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C. Peptides as substrates for the detection of enzymatic activity in vitro 
 Commonly, enzyme expression, activation and regulation are determined by 
Western Blot, enzyme-linked immunosorbant assay (ELISA), small molecule activity-
based probes, and peptide-modification based probes. All of the above methods rely on 
the mimic of protein-protein interactions essential to the maintenance of homeostasis in 
the body.   While the above assays can give information about the activation, mutation 
and indirectly the catalytic activity of an enzyme, all require a large number of cells if 
used to investigate cell lysates and none are capable of giving real-time kinetic data.8b 
Assay sensitivity with fewer cells required for detection has been achieved through the 
use of fluorescent peptide-based probes.  Peptides-derived from natural protein substrates 
have been successfully used as catalytic substrates of enzymes present in the cytosol of 
the cell.13  Peptides can be designed to be recognized and modified by the enzyme of 
interest with high specificity and activity.14  The addition of a fluorophore to the substrate 
peptide allows for quick sensitive detection of enzymatic activity that can be visualized 
by several types of instrumentation including fluorescence microscopy, fluorescence 
imaging of agarose gels, liquid chromatography coupled with mass spectrometry 
(LC/MS), and capillary electrophoresis with laser-induced fluorescence (CE-LIF).  
Below are four examples of how kinase and UPS activity have been detected in vitro 
using fluorescent peptides. 
_______________________ 
12Marusyk, A.; Almendro, V.; Polyak, K. Nat Rev Canc2012, 12, 323-34. 
13 Kennelly P.J.; Krebs, E.G. J Biol Chem1991, 266,15555-8. 
14Wu, D.; Sylvester, J.E.; Parker, L.L.;, Zhou, G.; Kron, S.J. Biopolymers2010, 94, 475-
86. 
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i. Chelation enhanced fluorescence (CHEF) 
 One way to detect kinase activity is to measure a change in the fluorescence of a 
kinase substrate peptide due to phosphorylation of the substrate.   This can be achieved 
by chelation enhanced fluorescence (CHEF) of the kinase substrate peptide through the 
phosphorylation-dependent coordination of a metal by a chromophore covalently 
attached to the kinase substrate peptide.15  Notable examples of such probes were  
reported by the Imperiali Group whose probes included a cysteine conjugated 
sulfonamide-oxime (C-Sox) chromophore within the region C-terminal or N-terminal to 
the kinase substrate region.16  Upon phosphorylation of the substrate peptide by kinases 
in in mammalian cell lysates, Mg2+ was simultaneously chelated by both the C-Sox 
chromophore and the phosphoryl group on the modified Ser/Thr residue which led to a 2-
5 fold increase in fluorescence.   Lukovic et al. were able to design CHEF-based probes 
with a higher degree of substrate specificity for several kinases including protein kinase 
C (PKC), Abelson kinase (Abl) and Akt1 (PKB) through a recognition-domain focused 
design strategy.  In addition, they tailored the kinase activity detection to a 96-well 
format that allowed for kinetic data to be determined based on fluorescence enhancement 
in vitro, demonstrating the potential for this assay to evolve into a high-throughput 
technique.     
___________________________ 
15Shults, M.D.; Janes, K.A.; Lauffenburger, D.A.; Imperiali, B. Nature Methods 2005, 2, 
277-84. 
16Luković, E.; González-Vera, J.A.; Imperiali, B. J Am Chem Soc2008, 130, 12821-27. 
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 While the majority of the activity measured by these CSox probes was due to 
phosphorylation by the desired kinase as shown by the use of kinase inhibitors and 
immunodepletion of the kinase of interest, there is still some probe modification by other 
kinases. Since there are over 500 known kinases in the cell, cross-reactivity in not 
unexpected but not desired.  Therefore continued improvement of substrate specificity is 
necessary before this technology can be applied to cell lysate assays in the clinic. 
ii. Quencher dyes 
Another strategy for specific kinase activity detection by a change in fluorescence is 
“Deep Quench” developed by the Lawrence Group.  Deep quench detects the restoration 
of fluorescence of the kinase-specific peptide substrate upon modification by the desired 
kinase.17  Kinase substrates designed for deep quench possessed a coumarin moiety 
conjugated to the positively charged peptide N-terminal to the modifiable Ser/Thr 
modification site.  Prior to phosphorylation, coumarin fluorescence was quenched in the 
presence of the negatively charged Acid Green dye.  Phosphorylation of the kinase 
substrate peptide and subsequent binding of the phosphorylated substrate to the 14-3-3 
protein domain displaced the Acid Green dye and led to the fluorescence of modified 
substrates.  This method allowed for the detection of protein kinase A (PKA) activity in 
mitochondrial membranes, with phosphorylation associated fluorescence observed over 
the autofluorescence associated with the organelles.  
_________________________ 
17Agnes, R.S.; Jernigan, F.; Shell, J.R.; Sharma, V.; Lawrence D.S. J Am Chem Soc 
2010, 132, 6075-80. 
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The dramatic fluorescence enhancement upon modification of these probes highlights 
the potential for similar peptide-based probes to be used ex vivo to monitor organelle 
specific-kinase activity in small sample sizes.  
iii. Fluorescence detection by capillary electrophoresis 
 It is possible to detect kinase activity through the use of fluorescent peptide-based 
probes without monitoring a change in fluorescence.  The Allbritton Group, in 
collaboration with the Lawrence Group, has reported the detection of Abl kinase activity 
in cell lysates using capillary electrophoresis coupled with laser-induced fluorescence 
(CE-LIF).18  This technique allows for the separation and fluorescence detection of both 
the modified and unmodified reporters within a capillary based on the difference in 
electrophoretic mobility due to the differing net charge of the phosphorylated and 
nonphosphorylated substrates.   
This method of detection is highly sensitive requiring only subnanomolar concentrations 
of modified peptides for fluorescence detection and was used to determine the catalytic 
efficiency of substrate phosphorylation.18  This technique, is also amenable to the 
simultaneous screening of several substrates at once, allowing for the concurrent 
detection of the activity of multiple enzymes.  
iv. Detection of UPS activity in vitro using short peptides 
 In addition to kinase activity, the activity of UPS enzymes, including the 
proteasome, can be detected using peptide substrates as well.   
 
_________________________ 
18Proctor, A.; Wang, Q.; Lawrence, D.S.; Allbritton, N.L. Analyst2012, 137, 3028-38. 
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Recently, the Allbritton Group has examined the collective activity of E1, E2, and E3 
UPS enzymes through the detection of ubiquitinated peptides bearing short modifiable 
recognition motifs known as degrons.19  Short fluorescent peptide sequences, 9-26 amino 
acids long, derived from proteins regulated by UPS-directed ubiquitination in the cell, 
were modified by E1, E2 and E3 enzymes in vitro.  Both monoubiquitination and 
polyubiquitination of the peptides substrates was observed by fluorescence imaging of 
the ubiquitinated substrates separated by gel electrophoresis.  The kinetics of peptide 
substrate ubiquitination and the minimal sequence required for modification were also 
assessed.  The Allbritton Group is currently adapting the assay for analysis by CE-LIF. 
D.  Peptides for the detection of intracellular enzymatic activity 
 The methods for kinase and UPS activity detection mentioned above as well as 
many other noteworthy approaches not mentioned here, mark great strides in the 
advancement toward enzymatic activity assessment in patient samples in the clinic.  
However, all of the above efforts were done in the context of purified enzymes or cell 
lysates and not within the cytosolic environment of intact cells. Detection of intracellular 
enzymatic activity requires the use of stable substrates and sensitive detection methods.   
Peptide-based fluorescent probes that meet the demands of ex vivo kinase activity 
detection have been developed by several groups using a variety of methodologies.  
Below we will briefly discuss three approaches used to successfully detect kinase or UPS 
enzymatic activity within intact cells. 
________________________ 
19Melvin, A.T.; Woss, G.S.; Park, J.H.; Dumberger, L.D.; Waters, M.L.; Allbritton, N.L. 
PLOS One2013, 8, e78082. 
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i. Caged compounds 
 A major challenge when measuring kinase activity inside of cells is the inability 
to accurately control and measure the start point of enzymatic activity.  One way to gain 
control of the intracellular kinase activity initiation is to use “caged” substrates.  
Molecular caging involves masking the substrate functional group required for enzymatic 
activity with an optically silent moiety via a photocleavable bond.  Photolysis of the 
caged compound at the desired zero time point, liberates the substrate to an optically 
active form.20  The caging strategy was first applied to the masking of end phosphate 
groups on cyclic AMP and ATP with a photolabile nitromethoxy phenyl group.   Upon 
photolysis biologically active forms of cyclic AMP and ATP were released and available 
for hydrolysis by cellular enzymes.21Recently, the caging strategy has been applied to the 
detection of PKA activity in erythrocytes by using a peptide-based substrate.  The 
Lawrence Group reported controllable PKA activity detection through the combined 
strategies of fluorescence quenching and phosphorylation site caging.22  The PKA 
substrate peptide contained a N-terminal fluorophore that was quenched in the presence 
of a negatively charged dye that noncovalently bound positively charged residues in the 
peptide chain via electrostatic interactions.   
________________________ 
20Lee, H.M.; Larson, D.R.; Lawrence, D.S. ACS Chem Biol2009, 4, 409-27. 
21(a) Forbus III, B.; Kaplan, J.H.; Hoffman, J.F. Biochemistry1978, 17, 3667-76. 
(b)Kaplan, J.H.; Ellis-Davies, G.C.; Proc Natl Acad Sci USA1988, 85, 6571-75. 
(c)Nargeot, J.; Nerbonne, J.M.; Engels, J.; Lester H.A. Proc Natl Acad Sci USA 1983, 
80, 2395-99. 
 
22Oien, N.P.; Nguyen, L.T.; Jernigan, F.E.; Priestman, M.A.; Lawrence, D.S. Angew 
Chem 2014, 126, 4056-59. 
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The phosphorylatable Ser residue was masked with the photolabile 4,5-dimethoxy-2-
nitrobenzyl group prior to loading into intact erythrocytes (red blood cells).  The reporter 
peptide was loaded into the red blood cells and fluorescence was detected only upon 
photolysis which liberated the Ser hydroxyl group for phosphorylation by PKA and the 
subsequent displacement of the negatively charged quencher dye, restoring the 
fluorescence of the N-terminal fluorophore.  This strategy demonstrated the power of 
using temporal detection for the measurement of kinase activity ex vivo. 
ii. Single cell CE 
 
 Collaborative efforts of both the Allbritton and Lawrence Groups has allowed for 
the detection of kinase activity in single cells using CE-LIF.23  PKB activity was detected 
using peptide substrates with unnatural amino acids incorporated intermittently 
throughout the substrate peptide chain to increase resistance to degradation by proteases 
without greatly sacrificing substrate efficacy.  These fluorescent probes were used to 
measure both the rates of phosphorylation and the rates of protease degradation based on 
the differences of the electrophoretic mobility of the phosphorylated substrates, 
nonphosphorylated substrates, intact reporter peptides and digestion fragments.  These 
probes also gave information about differing sites of substrate hydrolysis by proteases in 
cell lysates versus intact cells.    This report showed the potential of detecting kinase 
activity when the number of cells is the limiting factor such as the case with plasma cell 
analysis of MM patient tumors.  Their results also showed the potential of redesigning 
substrates for increased stability to proteolysis without sacrificing the capability of being 
modified by the desired enzyme. 
_________________________ 
23Proctor, A.; Wang, Q.; Lawrence, D.S.; Allbritton, N.L. Anal Chem2012, 84,7195-202. 
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iii. Detection of proteasome activity in live cells 
 The success of bortezomib in the clinic has increased the need for probes that can 
be used to detect proteasome activity inside intact patient cells.  The proteasome utilizes 
three different types of catalytic activity to degrade proteins, trypsin-like activity, 
chymotrypsin-like activity, and caspase-like activity.24  When screening potential 
proteasome inhibitors knowledge of which enzymatic activity is being blocked is highly 
valued.    Several fluorescent peptide-based probes with terminal electrophiles have been 
used to label proteasome substrates.   The general structure of several of these probes is a 
dye conjugated to the N-terminus of a tri-aminohexanoic acid (Ahx), tri-leucine (Leu), 
vinyl-sulfone (Dye-(Ahx)3-L3-VS) probe.   One example reported by Verdoes et al. 
utilized a membrane-permeable Bodipy-TMR-Ahx3L3VS which they used to detect 
proteasome activity in cell lysates, intact cells and in mice.24  When incubated with cell 
lysates in the presence of known proteasome inhibitors, the degree of proteasome 
labeling correlated to the degree of inhibitor.  These probes were even used to determine 
which subunit of the proteasome was being inhibited.  Though detection of proteasome 
labeling required cell lysis or fixation, the combination of membrane permeability and 
fluorescence detection of subunit specific labeling, lays a solid foundation for the use of 
these probes in a clinical setting. 
 
_________________________ 
24Verdoes, M.; Florea, B.I.; Menendez-Benito, V.; Maynar C.J.; Witte, M.D.; van der 
Linden, W.A.; van den Nieuwendijk, A.M.C.H.; Hofman, T.; Berkers, C.R.; van 
Leeuwen, F.W.B.; Groothuis, T.A.; Leeuwenburgh, M.A.; Ovaa, H.; Neefjes, J.J.; 
Filippov, D.V.; van der Marel, G.A.; Dantuma, N.P.; Overkleeft, H.S. Cell Chem 
Biol2006, 13, 1217-26. 
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E. Purpose of this work 
Though the use of peptides for the detection of enzymatic activity in the cell is 
advantageous due to their being excellent mimics of natural enzyme substrates, peptides 
comprised of canonical amino acids are also substrates for cytosolic peptidases. Peptide 
hydrolysis by aminopeptidases in the cytosol of immune cells such as plasma cells 
reduces peptides to their amino acid building blocks rapidly.25 Peptide-based enzymatic 
activity probes without features to make them resistant to hydrolysis by cytosolic 
proteases, are subject to destruction in the cellular environment before an activity-based 
readout can be detected.    
In the remaining three chapters we will describe our work to improve the protease 
resistance of fluorescent peptide probes used to detect kinase and UPS activity in 
malignant mammalian cell lines.  Specifically we will describe the design, synthesis, and 
performance of orninthine-rich β-hairpin peptide probes of enzymatic activity and the 
advantages and of utilizing secondary structure and noncanonical amino acids to impart 
protease resistance. 
_______________________ 
25Yewdell, J.W., Reits, E., Neefjes, J. Nat Rev Immunol2003, 3, 952-61. 
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Chapter II 
 
DESIGN, SYNTHESIS, AND CHARACTERIZATION OF PROTEASE-
RESISTANT β-HAIRPIN PEPTIDES CALLED PROTECTIDES 
 
A. Background 
Synthetic peptides have emerged as popular tools used to study cellular events, 
including molecular recognition, enzymatic activity, and membrane trafficking.1 The 
natural existence of peptides in biological systems and their vast potential for 
diversification allows them to be used as pharmaceuticals and diagnostics as well. There 
is a need for diagnostic testing that can measure enzymatic activity associated with the 
effectiveness of drug inhibitors in patient cells ex vivo.2 This need can be met through the 
use of fluorescently tagged peptide substrates that can be easily detected by spectroscopy, 
spectrometry, and/or electrophoresis, all methods already used in a clinical setting.3 
_____________________ 
1Ruttekolk, I.R.; Witsenburg, J.J.; Glauner, H.; Bovee-Geurts, P.H.M.; Ferro, E.S.; 
Verdurmen, W.P.R.; Brock, R. Mol Pharmaceutics2012, 9, 1077-86. 
 
2Mahindra, A.; Laubach, J.; Raje, N.; Munshi, N.; Richardson, P.G., Anderson, K. Nat 
Rev Clin Oncol2012, 9, 135-43. 
 
3Gonzalez-Vera, J.A. Chem Soc Rev2012, 41,1652-64. 
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The detection of kinase activity, the target of many pharmaceutical inhibitors, in live cells 
and in cell lysates has been reported using short unstructured peptides (6-30 residues) 
mimicking the native protein substrates.3-4  Incorporating such reporters as part of regular 
diagnostic screening would be particularly helpful in cancers of the immune cells like 
multiple myeloma (MM) and chronic myelogenous leukemia (CML) where kinase and 
other enzyme inhibitors are part of the first line of treatment.5  Currently, there are no 
diagnostic tests for either of these diseases that screen for the targeted enzyme activity, 
prior to treatment with drug inhbitors.6 
While proteins, due to their tertiary structure, are not susceptible to degradation 
unless specifically targeted in live cells by degradation pathway proteins, unstructured 
peptides are vulnerable because of their shorter length and lack of secondary and tertiary 
structure.7    In the cytosol of immune cells, aminopeptidases are predominantly 
responsible for peptidic digestion though the presence of endopeptidase activity has been 
reported.8 The crystal structures of two aminopeptidases, tripeptidyl peptidase II (TPP II) 
and leucine aminopeptidase (LAP) reveal catalytic cleft entrance dimensions of 30 Å × 
15 Å and 30 Å × 10 Å respectively, restricting access to short unstructured peptides.9 
_________________________ 
4Kunkel, M.T.; Ni, Q.; Tsien, R.Y.; Zhang, J.; Newton, A.C. J Biol Chem 2005, 280, 
5581-7. 
 
5(a) Placzek, E.A., Plebanek, M.P.; Lipchik; A.M.; Kidd, S.R.; Parker, L.L. Anal 
Biochem2010, 397, 73-8. (b) El-Amm, J.; Tabbara, I.A. Am J Clin Oncol 2013 Aug 7, 
[Epub ahead of print].  
 
6Palumbo, A.; Anderson, K. N Engl J Med2011, 364, 1046-60. 
7(a)Reits, E.; Griekspoor. A.; Neijssen, J.; Groothuis, T.; Jalink, K.; van Veelen, P.; 
Janssen, H.; Calafat, J.; Drijfhout, J. W.; Neefjes, J. Immunity2003, 18, 97-108. (b) Saric, 
T.; Graef, C.I., Goldberg, A.L. J Biol Chem2004, 279, 46723-32. 
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Well-folded β-hairpin peptides at the N-terminus of kinase activity reporter peptides can 
be used to increase their resistance to such proteases.We recently reported that the 
attachment of β-turn peptides, also known as β-bends, to the N-terminus of an 
unstructured protein kinase reporter peptide, successfully slowed its degradation by 
cellular proteases.10 
In this work, β-hairpin peptides were used to protect unstructured peptide-based 
probes from proteolytic degradation.  A β-hairpin peptide consists of two parallel or 
antiparallel peptide strands connected by a rigid turn or an unstructured loop, forming the 
most basic unit of a β-sheet, one of the most prevalent types of secondary structure found 
in proteins.11 In the past two decades, several studies have been dedicated to 
understanding the essential noncovalent and covalent interactions necessary to form 
stable well-folded β-sheets and β-hairpins outside of the context of full protein structure 
and tertiary contacts.12   There are five basic features that allow for short peptides to 
adopt stable β-hairpin conformations; 1) a turn-nucleating sequence, 2) cross-strand 
backbone H-bonding,  3) sidechain noncovalent interactions, 4) backbone rigidity, and 5) 
terminal covalent and noncovalent interactions to prevent fraying (Figure 2.1).    
__________________________ 
8Akkad, N.; Schatz, M.; Dengjel, J.; Tenzer, S.; Schild, H. Med Microbiol Immunol2012, 
201, 463-73. 
 
9Rockel, B.; Kopec, K.O.; Lupas, A. N.; Baumeister, W. Biochim Biophys Acta 2012, 
1824(1), 237-45. (b) Burley, S.K.; David, P.D.;, Taylor, A.; Lipscomb, W.N. Proc Natl 
Acad Sci1990, 87, 6878-82. 
 
10(a) Eker, F.; Griebenow, K.; Schweitzer-Stenner, R. J Am Chem Sci 2003, 125, 8178-
85. (b) Yang, S.; Proctor, A.; Cline, L.L.; Houston, K.M.; Waters, M.L.; Allbritton, N.L. 
Analyst 2013, 138, 4305-11. 
 
 
	   19	  
Investigation of these key features has allowed for the design of well-folded β-hairpin 
peptides with multiple applications, including binding nucleic acids, mimicking protein-
protein interactions, and imparting protease resistance.13  Additionally, folded β-bend 
peptides which contain only the amino acid residues necessary to nucleate a β-turn,have 
been reported .10 
β-hairpins were chosen as ideal protectides over other secondary structures such as 
alpha helices, due to their ability to tolerate diverse functionalization (including 
appending a peptide at the C-terminus) while maintaining their conformational folding in 
aqueous solutions.   While the use of peptidomimetics, including the incorporation of β 
and ϒ amino acids, has allowed for the development of short, stable peptide mimics with 
remarkable resistance to proteolytic degradation, the building blocks are generally 
moreexpensive.14  Also, we are designing protease resistant moieties to be covalently 
attached to L-amino acid peptide kinase substrates, and the use of peptidomimetics may 
necessitate additional synthetic steps.   
___________________________________ 
11Voet, D.; Voet, J. Biochemistry; 3rd ed.; John Wiley & Sons, Inc: Hoboken, NJ, 2004, 
pg 227-9. 
 
12Hughes, R. M.; Waters, M.L. Curr Opin Struct Biol2006, 16, 514-24. 
13(a) Stewart, A.L.; Waters, M.L. ChemBioChem2009,10, 539-44. (b) Wilger, D.J.; Park, 
J. H.:, Hughes, R.M.; Cuellar, M.E.; Waters, M.L. Angew Chem2011, 50, 12201-4. (c) 
Cline, L.L; Waters, M.L. Pept Sci2009, 92, 502-7. (d) Fasan, R.; Dias, R.L.A.; Moehle, 
K.; Zerbe, O.; Vrijbloed, J.W.; Obrecht, D.; Robinson, J.A. Angew Chem2004, 43, 2109-
12. (e) Cheng, Z.; Campbell, R.E. ChemBioChem 2006, 7, 1147-50. (f)Park, J.H.; 
Waters, M.L. Org Biomol Chem2013, 11, 69-77. 
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Short, thermodynamically stable, β-hairpins have been designed and synthesized 
through the optimization of turn sequences, the utilization of favorable sidechain-
sidechain interactions, the use of amino acids with high β-sheet propensity, and the use of 
salt bridges and capping motifs to prevent terminal fraying. 12,15 It has been reported by 
our group and others that optimization of beta-hairpin secondary structure conveys 
substantial resistance to proteolytic degradation.13c,e-f 
 
 
Figure 2.1 Anti-parallel β-hairpin peptide design features. Highlighted in green are 
residues participating in noncovalent sidechain interactions, in blue are residues with high 
β-sheet propensity, and the residue in red is the non-canonical amino acid ornithine.  
Backbone H-bonding is indicated by the hashed lines. 
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Previously, our group confirmed a direct correlation between secondary structure and 
the resistance of β-hairpin peptides to degradation by proteolytic enzymes.13c,f   The 
WKWK and the Trp Pocketβ-hairpin peptides (Table 2.1) were determined to be 95% 
and 99% folded in aqueous solvent, respectively, despite being only 12 amino acids in 
length.16  Each contained 11 canonical amino acids and 1 non-canonical amino acid 
(ornithine, Orn) and were found to be substantially more resistant to degradation by 
specific and nonspecific proteases than the unstructured control.13cThe sequence of 
WKWK was modified by replacing the turn sequence Asn-Gly (type I’ turn) with D-Pro-
Gly (type II’ turn).  The incorporation of the D-Pro-Gly turn sequence has been shown to 
enhance the stability of β-hairpins by nucleating a tighter turn.17 The resulting WKWK-
pGturn peptide (Figure 2.2 and Table 2.1), rich in basic amino acids (cleavage site of 
trypsin) and aromatic amino acids (cleavage site of α-chymotrypsin) showed resistance to 
degradation by trypsin, α-chymotrypsin and pronase E (a mixture of nonspecific 
proteases).13cThe WKWK-pGturn peptide showed a 10-fold greater stability to 
proteolytic degradation by pronase E in vitro over the unstructured control with a similar 
primary amino acid sequence.13cThis increased stability was attributed to its higher 
degree of fraction folded afforded by the type II’ turn sequence. 
________________________ 
14Frackenpohl, J.; Arvidsson, P.I.; Schreiber, J.V.; Seebach, D. ChemBioChem 2001, 
2,445-55. 
 
15Kier, B.; Shu, I.; Eidenschink, L.A.; Andersen, N.H. Proc Natl Acad Sci2010, 107, 
10466-71. 
 
16 (a) Butterfield, S. M.; Waters, M.L.; J Am Chem Soc2003, 125, 9580-1. (b) Butterfield, 
S.M.; Sweeney, M.M.; Waters, M.L. J Org Chem2005, 70 1105-14. (c) Rieman, A.J.; 
Waters, M.L. Biochemistry2009, 48, 1525-31. 
 
17Stanger, H.E.; Gellman, S.H. J Am Chem Soc1998, 120, 4236-37. 
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The following report describes ours efforts to further increase the lifetime of 
WKWK-pGturn by modifying its amino acid structure to increase folding and to slow 
or prevent hydrolysis by cytosolic peptidases. The modified β-hairpin peptides were 
designed to last for hours in vitro under harsh proteolytic conditions.   The resulting 
highly resistant β-hairpin peptides, which we call “protectides”, were then covalently 
attached to the N-termini of unstructured kinase and proteasome substrates to slow their 
degradation in cell lysates. The synthesis and performance of these full-length reporters is 
discussed in Chapter III of this work. 
 
Figure 2.2 Structure of the WKWK pGturnβ-hairpin peptide.13c 
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B. Design and Synthesis 
Building on the work published previously by our group (Cline and Waters, 2009), 
we made key changes to the amino acid sequence of WKWK-pGturn, based on the five 
design features mentioned above as well as the addition of non-canonical amino acids.  
The OWOWO peptide has the same primary sequence as WKWK pGturn except all of 
the basic natural amino acids were replaced with the non-canonical amino acid analog of 
lysine, ornithine (Figure 2.3, Table 2.1).  Although trypsin-like peptidases cleave at the 
carboxyl group of basic amino acids, the shortening of the Lys sidechain by one 
methylene group as is the case with Orn, slows the rate of hydrolysis by such enzymes.18   
Our group has demonstrated that Orn residues are capable of participating in diagonal 
cation-π interactions with aromatic sidechains and was therefore expected to participate 
in favorable interactions in the OWOWOpeptide.19  Since Orn carries a positive charge 
under physiological conditions, Orn residues were also added to increase the water 
solubility of otherwise hydrophobic peptides.   The ScramOWOWO(Scrambled-
OWOWO) peptide has the same primary amino acid sequence as the OWOWO peptide 
except the turn residues were positioned at the C-terminus of the peptide rather than in 
the middle (Figure 2.3).  This peptide served as an unstructured control.   The Trp 
Pocket peptide, which demonstrated proteolytic stability when tested previously, was 
also modified and investigated.13cThe Asn-Gly turn sequence was replaced with the 
stronger turn-nucleating sequence D-Pro-Gly, the N-terminal Arg was replaced with Orn, 
and 5(6)-carboxyfluorescein was attached to the sidechain of the Lys8 (Figure 2.3, Table 
2.1).  
_______________________ 
18Seely, J.H.; Benoiton, N.L. Can J Biochem1970, 48, 1122-31. 
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A long-standing challenge of designing and synthesizing short tightly-folded β-
hairpin peptides is terminal fraying.  To alleviate this problem, β-hairpins are commonly 
cyclized forming a covalent bond between the termini.4   However, one solution to 
fraying using noncovalent interactions was reported by Kier et al. and is referred to here 
as the Andersen capping motif.15The Andersen capping motif, “acyl-W-loop-WTG”, 
added +6 kJ/mol of stability to the β-hairpins reported.15This capping motif confers 
additive stability through a face-to-edge Trp-Trp interaction, bifurcated hydrogen 
bonding of the Thr residue with the N-terminal acyl group and the HN of Gly, and a CH-π 
interaction between the N-terminal Trp and the C-terminal Gly  (Figure 2.4).15  The 
Andersen capping motif was incorporated into the primary amino acid sequences of the  
AC1F, AC2F, AC4F, and AC5Fβ-hairpin peptides (Figure 2.4, Table 2.1) The cross-
strand cation-π sidechain-sidechain interaction that was present in the WKWK-pGturn 
peptide and the Trp Pocket peptide was incorporated into the AC4F peptide by 
positioning a Lys residue opposite a Trp residue on the non-hydrogen bonding face of the 
peptide. The “tryptophan zipper” (trpzip) motif reported by Cochran and coworkers was 
incorporated into the AC5F peptide through the placement of four Trp residues cross-
strand from each other on the non-hydrogen bonded face of the β-hairpin.20   The edge-
to-face π-π interaction between the indole sidechains of the trpzip motif have allowed for 
short β-hairpin peptides to be over 99% folded under physiological conditions.16c 
________________________ 
19Hughes, R.M.; Benshoff, M.L.; Waters, M.L.Chem-Eur J2007 13, 5753-64. 
 
20 (a) Cochran, A.G.; Skelton, N.J.; Starovasnik, M.A. Proc Natl Acad Sci2001, 98, 5578-
83. (b) Tatko, C.D.; Waters, M.L.; J Am Chem Soc2002, 124, 9372-3. 
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Finally, the D-isomer of the WKWK-pGturn peptide was made by replacing all of 
the L-amino acids with their D-isomer and the D-Pro residue was replaced with L-Pro.  As 
Gly is achiral it remained the same.  The D-isomer of WKWK-pGturn, referred to as 
theMirrorβ-hairpin peptide, was expected to have the greatest resistance to degradation 
since proteases are highly enantiospecific.  The scrambled version of the Mirror peptide, 
the ScramMirror peptide, was synthesized as an unstructured control (Figure 2.3).   
 The fluorophore 5(6)-carboxyfluorescein (FAM) was appended to the sidechain of 
the Lys or Orn at the i+4 position just after the turn sequence of the β-hairpin peptides 
and to Orn7 (Lys7) of the scrambled peptides.  The fluorophore was attached next to a 
turn residue of all β-hairpin peptides while all of the aromatic residues were placed on the 
opposite face to prevent the quenching of the FAM.21We expected that the incorporation 
of the fluorophore FAM to the sidechain of Lys or Orn, would also increase protectide 
resistance to trypsin-like peptidases, as the FAM would likely prevent proteolytic 
degradation due to steric hindrance. The attachment of FAM to each protectide allowed 
for their detection in cell-based assays described in Chapters III and IV of this work.  
________________________ 
21Cooper, W.J.; Waters, M.L. Org Lett2005, 7, 3825-8  
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Table 2.1 Name, amino acid sequence and secondary structure of peptides investigated 
for protease resistancea 
 
Peptide Name Sequence 2°  Structure 
ScramOWOWO Ac-OWVOWIO(FAM)QVOpG-NH2 Random Coil 
OWOWO Ac-OWVOVpGO(FAM)WIOQ-NH2 β-Hairpin 
OWOC Ac-COWVOVpGO(FAM)WIOQC-NH2 β-Hairpin 
WKWK.13c Ac-RWVKVNGOWIKQ-NH2 β-Hairpin 
WKWK-pGturn.13c  Ac-RWVKVpGOWIKQ-NH2 β-Hairpin 
AC4F** Ac-WVWVpGK(FAM)KIWTGOO-NH2 β-Hairpin 
Trp Pocket13c Ac-RWVWVNGOKILQ-NH2 β-Hairpin 
Trp Pocket dPro Ac-OWVWVpGK(FAM)OILQ-NH2 β-Hairpin 
Mirror Ac-DRDWDVDKDVPGDK(FAM) DWDIDODQ-NH2 β-Hairpin 
ScramMirror Ac-DKDWDVDRDWDIDK(FAM) DQDVDOPG-NH2 Random Coil 
AC1F** Ac-WIpGK(FAM)WTGO-NH2 β-Hairpin 
AC2F** Ac-WIpGK(FAM)WTGPSO-NH2 β-Hairpin 
AC5F** Ac-WTWIpGK(FAM)WTWTGOO-NH2 β-Hairpin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
________________________ 
aO represents the non-canonical amino acid ornithine. “Ac” represents acetylation of the 
N-terminus and C-terminus of each peptide was amidated. “AC” denotes peptides 
containing the Andersen Capping Motif. Secondary structure was determined by circular 
dichroism. 
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 Figure 2.3 Structured protectides and the unstructured control peptide evaluated in this 
work. (a) OWOWO (b) ScramOWOWO (c) Trp Pocket dPro (d) Mirror (e) 
ScramMirror.  Ornithine residues are highlighted in blue. 
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Figure 2.4Structures of β-hairpin protectides containing the Andersen capping motif. (a) 
Example peptide highlighting the noncovalent interactions of the Andersen capping 
motif. (b) AC1F (c) AC2F (d) AC4F (e) AC5F.  Residues part of the capping motif are 
highlighted in red.  Ornithine residues are highlighted in blue. 
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C. Results and discussion 
 
i. Structural characterization by circular dichroism  
 The secondary structure of the WKWK-pGturn peptide was characterized 
previously using circular dichroism (CD) and NMR. This 12-mer was folded greater than 
98% at 25°C in aqueous solvent.13c The secondary structure of the peptides listed in Table 
2.1 was determined CD spectroscopy (Figures 2.5, 2.6, 2.7).  The OWOWOpeptide had 
a local minimum near 218 nm indicative of a β-hairpin fold but it also had a minimum 
near 205 nm which has been reported in the spectra of other β-hairpin peptides with type 
II’ turns and aromatic residues (Figure 2.5).22   The exciton coupling between the indole 
rings of the Trp residues was observed by the presence of a local maximum at 225 nm 
and may be responsible for the shift in the minimum at 205 nm.  The minimum at 205 nm 
may also represent a distortion of the fold to accommodate the cross-strand cation-π 
interaction between Orn and Trp residues on the non-hydrogen bonded face. The 
scrambled peptide, ScramOWOWO, had a minimum near 195 nm which is 
characteristic of a random coil (Figure 2.5).13c  This observation confirmed that moving 
the turn sequence to the C-terminus of the peptide prevented the formation of any 
secondary structure though the identification of the amino acids and the chain length of 
the primary sequence was identical to that of the OWOWOβ-hairpin peptide.    The Trp-
Pocket dPro peptide had a minimum near 218 nm and maximum near 230 nm indicative 
exciton coupling between the cross-strand Trp-Trp pair (Figure 2.5).  The precedence of 
this strong Trp-Trp interaction in CD spectroscopy masked the minimum near 215 nm 
characteristically found in the CD spectra of β-hairpins and β-sheets.20a 
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Figure 2.5 Circular dichroism spectra of the ScramOWOWO, OWOWO, and Trp 
Pocket dPro peptides. Experiments were done at 40 µM peptide concentration in 10 mM 
sodium phosphate buffer, pH 8 at 25°C. ScramOWOWO (blue) was found to be a 
random coil while OWOWO and Trp Pocket dPro (green and purple respectively) both 
fold into a β-sheet conformation.  
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The CD spectra of the Andersen capped peptides was similar to that of the trizip peptides 
reported by Cochran and coworkers (Figure 2.6).20a  Since a major component of the 
noncovalent  capping motif is a cross-strand face-to-edge Trp-Trp interaction, the 
similarity between the spectra was expected.   Exciton coupling again was observed by 
the presence of a minimum near 218 nm and a local maximum near 230 nm.    The Trp-
Trp interactions masked the β-sheet peak at 215 nm in the spectra of all the Andersen 
capped β-hairpins (Figure 2.6).   
___________________ 
22Mahalashmi, R.; Shanmugam, G.;Polavarapu, P.L.; Balaram, P. Chembiochem 2005, 6, 
2152-8. 
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Figure 2.6 Circular Dichroism Spectra of the Andersen Capped peptides, AC1F (blue), 
AC2F (red), AC4F (black), and AC5F (green).  Experiments were done at 40 µM 
peptide concentration in 10 mM sodium phosphate buffer at 25°C.  All capped peptides 
fold into a β-sheet conformation and display strong Trp-Trp interactions with a minimum 
mean residue ellipticity near 218 nm and a maximum near 230 nm. 
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The secondary structure of the ScramMirror peptide and the Mirror peptide was 
determined using CD as well (Figure 2.7).  Since the WKWK-pGturn peptide was 
confirmed to be a well-folded β-hairpin by both CD and NMR, it was expected that its 
predominantly D-amino acid analog, the Mirror peptide would fold as β-hairpin as well.   
The CD spectra of the ScramMirror and Mirror peptides were mirror images of the CD 
spectra of the Scrambled-WKWK and WKWK-pGturn peptides.13cThe maximum near 
200 nm in the CD spectrum of the ScramMirror peptide is indicative of a random coil 
conformation.  The maximum near 218 nm in the spectrum the Mirror peptide indicates 
β-hairpin formation.  The local maximum near 230 nm isdue to Trp-Trp interactions. 
 
 
 
 
 
 
 
 
	   34	  
 
Figure 2.7 Circular dichroism Spectra of the Mirror and ScramMirror peptides. 
Experiments were done at 40 µM peptide concentration in 10 mM sodium phosphate 
buffer, pH 8 at 25°C.  The Mirror (orange) peptide folds into a β-sheet conformation 
indicated by a maximum near 215 nm.  The local maximum near 230 nm is due to Trp-
Trp interactions.  The ScramMirror (orange) peptide has a random coil conformation 
shown by the maximum near 195 nm. 
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ii. Determination of proteolytic stability in vitro 
Based on the work published by Cline and Waters as well as ease of synthesis, we 
selected six peptides to be tested in vitro for resistance to proteolytic degradation by a 
mixture of peptidases.  Pronase E, a mixture of endopeptidases and exopeptidases 
isolated from Streptomyces griseus, was chosen because of the wide range of targeted 
cleavage sites. Most peptidases in the cell are contained within organelles and not free in 
the cytosol, thus pronase E in vitro conditions were expected to be harsher than that of 
the cytosolic environment.  The WKWK-pGturnβ-hairpin peptide showed substantially 
greater resistance to pronase E than its unstructured counterpart even though its 
secondary structure was not locked by covalent cyclization.13cThe peptides chosen for the 
pronase E degradation assay are listed in Table 2.2.  The AC4F peptide was tested to 
determine the feasibility of using noncovalent capping motifs to increase resistance of β-
hairpin peptides to degradation by proteases.  The OWOWO peptide was tested to 
determine if any resistance to proteolytic degradation could be gained by the 
incorporation of a noncanonical amino acid with the same stereochemistry  found in 
natural proteins.   The ScramOWOWO peptide was included to determine the necessity 
of secondary structure when nearly half of the primary amino acid sequence contained 
noncanonical amino acids.   While the four peptides mentioned above were tested in 
triplicate, the ScramMirror and Mirror peptides were tested in duplicate and served as 
negative degradation controls since natural enzymes are highly stereospecific and thus 
these peptides were expected to be resistant to degradation. Since there was one natural 
amide bond in both peptides, (L-Pro-Gly), these peptides would also serve to give insight 
on whether or not secondary structure was necessary to protect that natural peptide bond.   
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Each peptide was incubated with pronase E at 37°C for 24 hours, at the enzyme 
concentration necessary for the ScramOWOWO peptide to have a half-life of less than 
10 minutes.  At 16 different time points, aliquots of the reaction mixtures were quenched 
with acetic acid and the amount of peptide degradation at each time point was determined 
by analytical RP-HPLC.  The acetic acid used to quench the reaction also served as an 
internal standard.  To determine the fraction of intact peptide remaining, the parent peak 
was integrated in the Empower Pro 2 analytical RP-HPLC software and was graphed as a 
function of time (Figure 2.8).   
 
Figure 2.8Analytical RP-HPLC analysis of peptide degradation by pronase E.  
Experiments performed with 100 µM initial peptide concentration, in 10 mM phosphate 
buffer, 100 mM NaCl, pH 7.6 at 37°C.  The ScramOWOWO peptide degraded fully 
after 15 minutes.  The WKWK pGturn, AC4F, and OWOWOβ-hairpin peptides show 
greater resistance to proteolysis. Graph represents the average peptide degradation of 
experiments done in triplicate. 
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The unstructured ScramOWOWO degraded quickly relative to the β-hairpin peptides 
including relative to the OWOWO peptide, as expected with half-lives of 7 minutes and 
315 minutes, respectively(Figure 2.8).  Unexpectedly, the ScramOWOWO peptide with 
four Orn residues and a bulky fluorophore attached which were absent from the WKWK-
pGturn peptide, still degraded much faster with a half-life of 7 minutes in comparison to 
40 minutes for WKWK pGturn.    This suggests that the inclusion of sidechain 
unnatural functional groups alone, in the absence of increased secondary structure, is not 
enough to impart substantial resistance to proteolytic degradation.  
 The AC4F and the OWOWOβ-hairpin peptides both contain residues capable of 
engaging in cross-strand cation-π interactions to impart stability just like those found in 
WKWK pGturn, however these two peptides have additional features to increase 
stability to proteolytic degradation.  The AC4F peptide contained the Andersen capping 
motif, which includes a number of energetically favorable noncovalent terminal 
interactions.15 These additional terminal contacts, which presumably reduced terminal 
fraying,are likely responsible for the increased half-life of AC4F over WKWK pGturn.  
Since the addition of Orn residues and a fluorophore alone did not make much difference 
in the rate of degradation of the ScramOWOWO peptide, this greater half-life of AC4F 
over WKWK pGturn can be attributed to its improved folding.   The most stable peptide 
however was the OWOWO peptide, with 4 internal and terminal Orn residues.  Though 
it lacks the capping motif, the combination of non-canonical amino acids and secondary 
structure proved to be ideal, resulting in half-life of 315 minutes.   
 The Mirror and ScramMirror peptides appeared to show no degradation over 24 
hours in their analytical RP-HPLC chromatograms (Figures 2.10, 2.11).  However, 
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without mass spectrometry confirmation, it cannot be said with certainty that these two 
peptides were not cleaved.   The only scissile bond of the Mirrorβ-hairpin available to 
the proteases is in the middle of the peptide. If the proteases had cleaved the Mirror 
peptide, the resulting fragments would have differed significantly in polarity and size and 
therefore would have likely had an elution time different from the intact parent peptide.  
Since only one peak was seen throughout the 24-hour study, it is highly likely that no 
degradation took place.  The native amide bond of the ScramMirror peptide however 
was at the C-terminus and could have been readily accessed by the pronase E proteases.  
Cleavage at this bond would have resulted in a peptide fragment that would be similar in 
size and polarity to the parent peptide and could therefore co-migrate with the parent 
peptide.  Any future studies done with these peptides would require mass spectrometry 
confirmation of their resistance to proteolytic degradation. 
 
Table 2.2. Peptide Dimensions and Resistance to proteolysis by pronase Ea 
 
Peptide Name β-Hairpin Dimensions (Å) t1/2 (min) 
ScramOWOWO ---- 7 
WKWK-pGturn 21 x 13 40 
AC4F ---- 143 
OWOWO 21 x 12 315 
Mirror 21 x 13 ND 
ScramMirror ---- ND 
 
 
 
 
___________________ 
at1/2 time necessary for 50% of peptide to be degraded by pronase E; ND denotes No 
Degradation observed; Studies with ScramOWOWO, WKWK pGturn, AC4F and 
OWOWO were done in triplicate; ScramMirror and Mirror were tested in duplicate.β-
hairpin dimensions were determined using Spartan’04 software 
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D. Conclusions 
 We successfully designed short (9-14 residues) well-folded β-hairpin peptides 
that showed resistance to rapid degradation by proteolytic enzymes.  By using a 
strong turn-nucleating sequence, cross-strand noncovalent interactions, and strong 
noncovalent interactions between the termini, all of the peptides designed showed the 
desired β-hairpin or random coil structure (Figures 2.5, 2.6, 2.7).  The redesigns of 
WKWK pGturn increased its resistance to degradation by pronase E  by 7-fold as 
shown in Figure 2.8 and Table 2.2.  The OWOWO peptide was found to have the 
longest half-life, with the exception of the D-amino acid peptidesMirror and 
ScramMirror, with 50% degradation occurring after 5 hours. The WKWK pGturn 
peptide exhibited a half-life of 40 minutes, demonstrating that the ornithine 
substitutions and FAM significantly increase the resistance of the peptide to 
proteolytic degradation.  The AC4F peptide, with the noncovalent capping motif 
reported by Kier et al., showed greater protease resistance than the WKWK pGturn 
peptide with a half-life of 143 minutes.   Resistance to proteolytic degradation may 
not correlate with degree of folding and the number of unnatural amino acids equally.  
AC4F with its terminal capping motif may be a better folded β-hairpin than the 
OWOWOpeptide, though this cannot be confirmed without further investigation with 
NMR and/or CD thermal melts.  Replacing all of the basic amino acids with Orn 
could possibly increase the resistance of the AC4F peptide.  The Mirror and 
ScramMirror peptides did not appear to be degraded at all when analyzed by 
analytical RP-HPLC, however these results must be confirmed by mass spectrometry 
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where the presence of degradation products similar in mass and polarity would be 
revealed. 
E. Ongoing Work 
While a half-life of 315 minutes is a 45-fold improvement over the control peptide, an 
ideal protectide would be made of predominantly L-amino acids and would have a half-
life of at least 24 hours.  Recently, the cyclized version of OWOWOwas synthesized in 
an attempt to achieve this goal.  The OWOC peptide (Table 2.1, Figure 2.9) includes a 
cysteine residue at both termini whichallows for covalent cyclization through reaction 
with methyl 3,5-dibromobenzoate (Scheme 2.1).  This method of cyclization was adapted 
from the work done independently by Timmerman and coworkers and Heinis coworkers 
used to cyclize linear peptides.23  The advantage of this method of cyclization as opposed 
to a disulfide bridge between the two termini is that the thioether bonds are resistant to 
reduction in the cytosolic environment.  Cyclization of OWOC using a dibromoxylene is 
expected to also provide increased resistance to hydrolysis by peptidases at the termini.  
Comparisons between noncovalent and covalent solutions to terminal fraying and the 
positioning of non-canonical amino acids can be made based on the half-lives of the 
OWOCyc (Figure 2.9) peptide and the AC4F peptide in the presence of proteases.  
Based on the long half-life of the uncyclized OWOWOβ-hairpin peptide in the presence 
of endopeptidases and exopeptidases from pronase E, the cyclized version is expected to 
remain intact even longer.   The ScramOWOWO, WKWK pGturn, AC4F, OWOWO, 
and OWOCyc peptides will be incubated with HeLa whole cell lysates at 37°C and their 
lifetimes will be compared. It will be interesting to compare the differences in the 
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lifetimes of these peptides between cell lysates and pronase E.  Currently, work is also 
being done to characterize the secondary structure of the OWOCyc peptide by CD.   
 
 
Scheme 2.1. Cyclization of OWOC to form OWOCyc 
 
 
 
Figure 2.9.Structures of the OWOC and the OWOCyc peptides. (a) OWOC peptide. (b) 
OWOCyc. The functional groups participating in the cyclization are highlighted in red.   
 
________________________  
23(a) Timmerman, P.; Beld, J.; Puijk, W.C.; Meleon, R.H.; ChemBioChem2005, 6, 821-4. 
(b) Chen, S.; Morales-Sanfrutos, J.; Angelini, A.; Cutting, B.; Heinis, C. 
ChemBioChem2012, 13, 1032-38.  
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F. Experimental Section 
Peptide Synthesis and Purification 
 Peptides were synthesized using manual or automated standard solid phase 
peptide synthesis (Thuramed Peptide Synthesizer, CEM Liberty1 Microwave Peptide 
Synthesizer) using Fmoc protected amino acids on 0.06-0.08 mmol of CLEAR Amide 
resin from Peptide International.   Four equivalents of standard amino acids were used for 
each peptide synthesis while 1.5-4 equivalents of noncanonical amino acids and 
fluorophores were used.  All peptides were acetylated at the N-terminus by treating the 
resin with 5% acetic anhydride and 6% 2,6-lutidine in 5 mL of DMF bubbling with N2 for 
40 minutes.   5(6)-Carboxyfluorescein (FAM) was coupled to the ε-NH of lysine or the δ-
NH of ornithine at the i+4 position of the beta-hairpins or the centrally located amino 
acids of the scrambled sequences.  The sidechains of these amino acids were orthogonally 
protected with an allyloxycarbonyl group (N-Alloc) or with 1-(4,4-dimethyl-2,6-
dioxocyclohex-1-ylidene-3-methylbutyl (N-ivDde).   Alloc removal was done based on 
the protocol published by Pazos et al.24 The removal of ivDde from the sidechain of 
lysine or ornithine was accomplished by treating the peptide resin 3 x 2 mins with 20 mL 
of 2% hydrazine monohydrate in DMF bubbling with N2 followed by washing with 
DMF, MeOH, DCM. Following deprotection, FAM was coupled using 2-4 equivalents of 
FAM, 5 equivalents of PyBOP/HOBt and 8 equivalents of DIPEA in 5 mL of DMF and 
allowed to bubble with N2 for 4-8 hours.   
_________________________ 
24Pazos, E.; Jiménez-Balsa, A.; Maszareñas, J.L.;  Vázquez, M.E. Chem Sci2011, 2, 
1984-87 
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Double coupling was sometimes required.  Kaiser testing was done after the capping, 
deprotection and coupling steps.  Peptides without cysteine were cleaved from the resin 
in 9.5:2.5:2.5 trifluoroacetic acid (TFA), TIPS and water respectively for 3-4 hours. 
Peptides containing cysteine were cleaved using 9.4:2.5:2.5:1 TFA, EDT, water and TIPS 
respectively for 3-4 hours. The TFA was evaporated and the cleaved peptides were 
precipitated using cold ethyl ether and extracted with water.  Extracted peptides were 
lyophilized and then purified using semi-preparative RP-HPLC on a Vydac C18 semi-
preparative column with a gradient from ‘0 to 100% B’ in 45-120 minutes.  Solvent A 
was 95% water, 5% acetonitrile and 0.1% TFA and Solvent B was made of 95% 
acetonitrile, 5% water and 0.1% TFA.  Purified peptides were lyophilized and their 
synthesis and purity confirmed by ESI-TOF or MALDI-TOF using 2,5-dihydroxybenzoic 
acid matrix. 
 
Peptide Concentration Determination 
 
UV/Vis was used for the concentration determination of each peptide in 10 mM sodium 
phosphate buffer (100 mM NaCl, pH 7.48 for protease degradation studies) pH 8 using 
FAM abosorbance at 492 nm, ε492 = 78,000 M-1 cm-1, for peptides with FAM or by 6M 
guanidinium chloride denaturation and tryptophan absorbance at 280 nm ε280 = 5690 M-
1cm-1  for peptides without FAM. 
 
Circular Dichroism Spectroscopy  
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CD spectroscopy data was collected using an Applied Photophysics Chiroscan Circular 
Dicroism  Spectrophotometer.  Spectra were generated at 25 °C with a wavelength scan 
260 nm to 185 nm, with 0.5 second scanning in a 0.1 cm cell.  Peptide concentrations of 
40 µM in 10mM sodium phosphate buffer, pH 8.0 (peptides with FAM) or pH 7.4 
(peptides without FAM) were used. 
 
Peptidase Concentration Determination 
 
Pronase E enzymes from Streptomyces griseus were purchased as a lyophilized powder 
from Sigma-Aldrich (EC 3.4.24.31). Stocks were made by bringing up 5 mg of enzyme in 
15 mL of 10 mM sodium phosphate buffer, 100mM NaCl pH 7.48 (0.33 mg/mL). 1 ml 
aliquots were stored in the -80°C freezer for future use.  As 7 µL of enzyme stock in 1.3 
mL of peptide solution completely digested the ScramOWOWO peptide in 15 minutes, 
this was the volume of enzyme used in all protease studies. 
 
Peptide Degradation by Pronase E  
 
The enzymatic proteolysis procedure was adapted from Cline and Waters.13c  The 
reaction was initiated by the addition of 7 µL of pronase E stock solution to 1.293 mL 
solution of 100 µM peptide in 10 mM sodium phosphate buffer, 100 mM NaCl pH 7.5 at 
37°C .   75 µL aliquots were taken at 0, 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 
720, 1080, 1440 minutes and quenched with 10 µL of acetic acid and 15 µL of buffer 
generating a total volume of 100 µL.  25 µL of each quenched sample was injected on the 
analytical RP-HPLC  (Waters) and the fraction of peptide remaining at each time point 
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was determined based on the absorbance of each peptide at 214 nm and/or 280 nm.  Peak 
integrations were done using Empower Pro 2 software. The acetic acid peak was used as 
an internal standard.  The fraction of full-length peptide at each time point was 
determined by dividing the total peak area of the full-length peptide at each time point by 
the area of the acetic acid peak.  This number was divided by the corresponding value of 
the zero time point.   
Peptide Cyclization  
 
To a solution of OWOCys peptide (20 µM final concentration) in 20 mM 
NH4HCO3/(NH4)2HCO3, pH 9.64, methyl 3,5-bis(bromomethyl)benzoate (in 80:20 buffer 
and CH3CN)  was added slowly (20%/hr, 224 µM final concentration) in the presence of 
500 µM TCEP . The reaction proceeded at 34°C in the dark for 6 hours and monitored by 
MALDI mass spectrometry using 2,5-dihydroxybenzoic acid as the matrix.  The total 
reaction volume was 250 µL, containing 150 µL peptide and 100 µL methyl 3,5-
(dibromomethyl)benzoate. 
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Figure 2.10.  Analytical RP-HPLC chromatograms of the Mirror peptide incubated with 
pronase E for different time periods.  Reactions were quenched with acetic acid (peak 
migration time around 2 minutes) at (black) 0 m, (blue) 5 m, (green) 10 m, (cyan) 15 m, 
(magenta) 30 m, (burgundy) 45 m, (midnight blue) 60 m, (red) 90 m, (denim blue) 120 
m, (orange) 180 m, (periwinkle) 240 m (pink) 300 m, (sky blue) 360m, (peach) 720 m, 
(purple) 1080 m, (sea green) 1440 m (Time points listed from top to bottom).  Peptides 
were detected by absorbance at 220 nm. 
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Figure 2.11. Analytical RP-HPLC chromatograms of the ScramMirror peptide 
incubated with pronase E for different time periods.  Reactions were quenched with 
acetic acid (peak migration time around 2 minutes) at (black) 0 m, (blue) 5 m, (green) 10 
m, (cyan) 15 m, (magenta) 30 m, (burgundy) 45 m, (midnight blue) 60 m, (red) 90 m, 
(denim blue) 120 m, (orange) 180 m, (periwinkle) 240 m (pink) 300 m, (sky blue) 360m, 
(peach) 720 m, (purple) 1080 m, (sea green) 1440 m (Time points listed from top to 
bottom).  Peptides were detected by absorbance at 220 nm. 
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Chapter III 
 
COVALENT LINKAGE OF PROTECTIDES TO UNSTRUCTRURED KINASE 
AND PROTEASOME SUBSTRATES FOR ENHANCED PROTEASE STABILITY 
 
A. Background 
Emergence of molecularly targeted therapeutics 
Increased awareness of the complexity of healthy cell homeostasis and diseased cell 
dynamics has led to the emergence of disease-specific molecularly targeted therapeutics, 
particularly in the treatment of hematologic cancers such as multiple myeloma (MM) and 
chronic myelogenous leukemia (CML).  The development and FDA approval of a 26S 
proteasome inhibitor for the treatment of MM in the past decade and a half, have 
extended the median survival from 2-3 years after diagnosis to 5-7 years.1     The 
existence of the Philadelphia chromosome, a chromosomal translocation gene fusion 
product (t(9;22)(q34;q11)) which results in a constitutively active oncoprotein, BCR-Abl 
tyrosine kinase, has long since been known to be the culprit of most cases of CML.2  The 
development  of Abl tyrosine kinase inhibitors for the treatment of CML has extended 
patient prognosis from 3-4 years in 1999, to 10+ years in 2014.2 
________________________________ 
1 (a) Samson, D. Postgrad Med J, 1994, 70, 404-10. (b) Mahindra, A.; Laubach, J.;Raj, 
N.; Munshi, A.; Richardson, P.G.; Andersen, K. Nat Rev Clin Oncol, 2012, 9, 135-43. 
 
2Jabbour, E.; Kantarjian, H. Am J Hematol, 2014, 89, 547-556. 
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Combination therapy, involving the use of multiple inhibitors simultaneously to treat a 
patient has been a long-standing practice even prior to knowledge of inhibitory 
mechanism of action.  Perifosine and TAS-117, allosteric inhibitors of protein kinase B 
(PKB also known as Akt), have shown synergistic anti-MM tumor activity when coupled 
with proteasome inhibitors and other immunodulatory drugs used to treat MM.3 Though 
the treatments described above have been very successful in the treatment of MM and 
CML, the success has been dampened in recent years by the formation of drug-resistant 
tumor cell populations.1,2 
The development of diagnostic tests specific for determining the outcome of patients 
treated with targeted therapeutics is lagging far behind that of drug development.  
Diagnosis of MM and CML primarily involves detection of cytogenetic abnormalities in 
biopsy samples and detection of disease-specific proteins in the blood and urine.4   
Ideally, diagnostic testing would include direct testing for aberrant enzymatic activity in 
biopsied cells to determine which protein inhibitors would most benefit the patient.  Also, 
these assays could be used to test patient cells during follow-up visits to directly 
determine if the inhibitors are successfully blocking enzymatic activity and if resistant 
tumor cell populations have arisen.  
________________________________ 
3(a) El-Amm, J.; Tabbara, I.A. Am J Clin Oncol, 2013 [Epub ahead of print]. (b)Mimura, 
N.; Hiseshima, T.; Shimomura, T.; Suzuki, R;, Ohguchi, H.; Rizq, O.; Kikushi, S.; 
Yoshida, Y.; Cottini, F.; Jakubikova, J.,;Cirstea, D.; Gorgun, G.; Minami, J.; Tai, Y.T.; 
Richardson, P.G.; Utsugi, T.; Iwama, A.; Anderson K.C.  Cancer Res, 2014, [Epub ahead 
of print].  
 
4(a) Kyle, R.; Rajkumar, A.V. Blood, 2008, 111, 2962-72,(b) Bataille, R.; Annweiler, C.; 
Beauchet, O. Clin Lymphoma Myeloma Leuk, 2013, 13, 635-7. 
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Molecular activity screening would be useful in clinical trials and in the early stages of 
testing new drugs as well. 5 The goal of many clinical trials goes beyond detection of 
anti-tumor activity.  In addition to tumor growth, researchers and clinicians are 
monitoring the correlation, if any, between the anti-tumor response and change in 
biomarker levels, particularly plasma protein levels.2   Clinicians in each trial try to match 
patient outcome with an easily detected change in molecular events.     The Allbritton 
Group in collaboration with the Lawrence Group at UNC have done extensive work to 
develop assays that would allow rapid intracellular enzymatic activity analysis in single 
intact patient cells collected from biopsy samples.6  The foundation of these assays is the 
use of fluorescent peptide substrates that can be recognized and modified specifically by 
the protein of interest and then detected by single cell capillary electrophoresis coupled 
with laser-induced fluorescence (CE-LIF).   While single cell CE-LIF is a highly 
sensitive semi-automated technique that can be used to detect subnanomolar 
concentrations of modified peptides rapidly after single cell injection, rapid degradation 
of reporter peptide by cytosolic peptidases in the cell has hampered progress toward 
marketing this technique. 
_________________________________ 
5 Rodon, J.; Dienstmann, R.; Serra, V.; Tabernero, J.Nat Rev Clin Oncol, 2013, 10,143-
53. 
 
6(a) Sims, C. E.; Allbritton, N.L. Curr Opin Biotechnol, 2003, 14, 23-8. (b) Kovarik, 
M.L.;  Allbritton, N.L. Trend Biotechnol, 2011, 29, 222-30. (c) González-Vera, J. A. 
Chem Soc Rev, 2012, 41, 1652-64. 
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The fate of peptides in the immune cell 
One of the biggest obstacles in studying real-time cellular events using unstructured 
peptides is their susceptibility to degradation by cytosolic peptidases.7  The cytosol of 
immune cells has particularly high protease activity due because of their roles in 
recognizing and signaling the presence of foreign invaders including viruses and bacteria.  
Degradation of inactivated cellular proteins or of foreign invader proteins usually begins 
with a big proteolysis complex known as the 26S proteasome.  Proteosomal degradation 
takes place in both the nucleus and cytosol of the cells, allowing for rapid protein 
turnover regardless of protein location in the cell.  Proteins in immune cells are first 
tagged for degradation by the 26S proteasome or the immunoproteosome, a large 
degradation complex very similar to the 26S proteasome, but has a few differing subunits 
in the catalytic cleft.8  Proteasomal degradation of the targeted protein is initiated at the 
C-terminus of the protein and results in the emergence of oligopeptides of various 
lengths, usually between 4-20 amino acids long.  The proteasome is the only confirmed 
carboxypeptidase in the cytosols of immune cells.  Oligopeptides are further digested in 
the cytosol only (no peptidase other than the proteasome is known to exist in the nucleus) 
by aminopeptidases and a few endopeptidases.7  Most peptides are rapidly hydrolyzed 
down to their individual amino acids but a few escape degradation and are used for 
immune cell presentation.7 
_________________________ 
7Yewdell, J.W.; Reits, E.; Neefjes, J.  Nat Rev Immunol, 2003, 952-61. 
8Kramer, H.B.,;Nicholson, B.; Kessler, B.M.; Altun, A. Biochim Biophys Acta, 2012, 
1823, 2029-37. 
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These few surviving peptides are thought to be bound by chaperones that protect them 
from complete degradation.  The peptides are trimmed further at their N-termini to make 
them the correct size for antigen presentation, and then they are trafficked to the cell 
surface where they are bound and presented to sentinel T cells by the major 
histocompatibility complex (MHC).7 
N-terminal protection  
While trying to elucidate the mechanism of MHC class I antigen presentation on 
immune cells, Mo et al. reported that N-terminal acetylation of antigen peptides 
prevented their presentation by the MHC proteins because they could not be trimmed to 
the appropriate length for presentation by aminopeptidases.9  (Evidence of antigen 
peptide cleavage by endopeptidases was observed however.)   Building on their work, 
Reits et al. designed a peptide that was resistant to hydrolysis by aminopeptidases found 
in human melanoma cell line, by capping it at the N-terminus with an Fmoc group.10   
Shibata et al. attached the 10-amino acid cyclic RES-703-1 peptide to the N-terminus of 
biologically active unstructured substrate peptides, and observed up to a 4-fold increase 
in resistance in the presence of trypsin and chymotrypsin in vitro over 4 hours.11 
________________________ 
9 Mo, X.Y.’ Cascio, P.; Lemerise, K.; Goldberg, A.L.; Rock, K. J Immunol, 1999, 163, 
5851-9. 
 
10Reits, E.; Griekspoor, A.; Neijssen, J.; Groothius, T.; Jalink, K.; van Veelen, P.; 
Jansssen, H.; Calafat., J.; Drijfhout, J.W.; Neefjes, J. Immunity, 2003, 18, 97-108. 
 
11Shibata, K.; Suzawa, T.; Soga, S.; Mizukami, T.; Yamada, K.; Hanai, N.;Yamasaki, M. 
Bioorg Med Chem Lett, 2003, 13, 2583-86.  
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Inspired by these results, recently we published Abl kinase peptide substrates with 
increased stability due to their being capped at their N-termini with a cyclized β-bend 
peptide.12 We found that appending short cyclized and uncyclized β-bend peptides (5-12 
amino acid peptides with a reverse turn nucleating sequence) to the N-terminus of an Abl 
kinase reporter extended its half-life in the presence of cytosolic proteases by 10-40 fold.  
The substrate stability increased proportionally with the size of the β-bend protecting 
peptide and the cyclized β-bends provided the greatest improvement in stability over the 
unprotected control.  The β-bend protected Abl kinase reporter was then microinjected 
into Ba/F3 BCR-Abl cells and phosphorylation was observed.   The unprotected 
substrate, when microinjected into cells, degraded too rapidly for phosphorylation to be 
observed.  These results showed the true potential of employing a β-bend N-terminal 
protection strategy to increase enzyme substrate stability in diagnostic assays.  
Continuing with this strategy, we designed β-hairpin peptides (similar to β-bends except 
they are longer to utilize more cross-strand sidechain interactions to increase folding) that 
are highly resistant to degradation under harsh proteolytic conditions in vitro (Chapter II 
of this work).  Below we describe the fate of kinase substrate peptides with our protease-
resistant β-hairpin peptides appended to their N-termini. 
_______________________ 
12 Yang,S.; Proctor, A., Cline, L.L.; Houston, K.M.; Waters, M.L., Allbritton, N.L. 
Analyst, 2013, 138, 4305-11. 
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B. Design and Synthesis 
The β-hairpin protectide 
To begin probing the possibility of using β-hairpins as tools to study enzymatic 
events within cells, their stability in the presence of proteolytic enzymes was determined 
in vitro.  Select β-hairpin peptides were incubated for 24-hours with pronase E, a cocktail 
of endopeptidases and exopeptidases from Streptomyces griseus.  The proteolysis 
reaction was quenched at different time points and the amount of intact β-hairpin peptide 
remaining was monitored by analytical RP-HPLC (Chapter II, Figure 2.9, Table 2.2).  
The most stable β-hairpin peptide was Mirror peptide (no degradation observed over 24-
hours).    This β-hairpins along with ScramMirror (a random coil peptide that also 
showed no degradation in the presence of pronase E as monitored by analytical RP-
HPLC), were selected to protect unstructured kinase and proteasome substrate peptides 
from degradation, and were henceforth referred to as protectides.  
Kinase and proteasome substrate peptides 
 
Protectides were attached to the N-termini of two different peptide substrates of 
clinically relevant enzymes, including protein kinase B (PKB) and BCR-Abl kinase 
(Abl).   Each of the peptide substrates were investigated previously for their enzyme 
modification specificity and efficacy.12-13 
___________________________________ 
13 (a) Kunkel, M.T.,;Ni, Q.; Tsien, R.Y.; Zhang, J.; Newton, A. J Biol Chem, 2005, 280, 
5581-87. (b) Bonger, K.M.;Chen, L.C.; Liu, C.W.; Wandless, T.J. Nat Chem Biol, 2011, 
7, 531-7. 
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The kinetics of degradation by cytosolic enzymes has also been reported for the PKB 
substrate peptide and the Abl kinase substrate.12   Listed in Table 3.1 are the amino acid 
sequences of the protectides and of the kinase and proteasome substrates investigated 
here.   These two enzyme substrate peptides were chosen because inhibitors of their 
corresponding enzymes are currently in use as therapeutics or are in advanced stages of 
clinical trial investigation .1-3 
Protectide-substrate synthesis 
Full-length reporter peptides complete with a protectide region, a polyethylene glycol 
(PEG) spacer, an enzyme substrate region, and a fluorophore (FAM) attached to the 
protectide for detection, were synthesized linearly by solid phase peptide synthesis 
(SPPS) using standard Fmoc chemistry (Scheme 3.1).  Each peptide was purified by 
semi-preparative RP-HPLC and purification was confirmed by ESI or MALDI mass 
spectrometry.  The structures of the full-length reporters are shown in Figure 3.1.  Work 
done previously by Dr. Shan Yang in the Allbritton Group evaluated the necessity of 
including a spacer between the protecting N-terminal group and the C-terminal substrate 
portion of kinase reporter peptide.14  She found that a flexible space is required to allow 
unhindered phosphorylation by the desired enzyme and that the spacer length significant.  
Building on her work, we chose to synthesize reporters with PEG2, (PEG2)2, or PEG4 
spacers (Figure 3.3).   
 
 
_____________________________________ 
14Yang, S. Development of Peptidase Resistant Reporters for Intracellular Enzymatic 
Activity. University of North Carolina at Chapel Hill, Dissertation, 2011.pg 220 
 
	   56	  
Amino acid spacers such as polyglycine, poly-β-alanine, and poly-aminohexanoic acid 
were considered but failure to synthesize these full-length reporters with reasonable 
yields caused us to proceed only with PEG spacers. The sequences of the protectide-
substrate reporter investigated for resistance to proteolytic degradation in vitro are listed 
in Table 3.2. 
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Table 3.1  Sequences of Protectides and Kinase Substratesa 
 
Name Sequence Protectide or Substrate 
Mirror Ac-DRDWDVDKDVPGDK(FAM)DWDIDODQ-NH2 Protectide 
ScramMirror Ac-DRDWDVDKDVPGDK(FAM)DWDIDODQ-NH2 Protectide 
FPKB13 FAM-RKRDRKGTLGI-NH2 Protein kinase B substrate 
Abl12 FAM-EAIYAAPFAKKK-NH2 Abl kinase substrate 
 
Table 3.2  Names and Sequences of Protected and Unprotected Kinase Reporter Peptides 
 
 Name Sequence 
MP4B Ac-DRDWDVDKDVPGDK(FAM)DWDIDODQ-PEG2-PEG2-RKRDRKGTLGI-
NH2 
SMP4B Ac-DRDWDVDKDVPGDK(FAM)DWDIDODQ-PEG2-PEG2-RKRDRKGTLGI-
NH2 
ScramOWOWO Ac-OWVOWIO(FAM)QVOpG-NH2 
MD-PEG4-Abl Ac-DRDWDVDKDVPGDK(FAM)DWDIDODQ-PEG4- EAIYAAPFAKKK-NH2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
___________________________________ 
aKinase substrate in bold; Phosphorylatable residue highlighted in red; FAM-6-
carboxyfluorescein fluorophore for detection; p denotes DProline; M/MD denote the 
Mirror protectide, SM denotes the ScramMirror protectide. 
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Figure 3.1 Structures of protectides,a) Mirror b) ScramOWOWO d) ScramMirror. 
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Figure 3.2 Structures of kinase substrates a) Protein kinase B substrate (PKB), Abl 
kinase substrate (Abl).  Phosphorylatable residues are highlighted in red. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
H
H
N N
H
O
O
O
O
H
N N
H
H
N N
H
H
N
O
O
O
O
N
H
H
N N
H
O
O
O
NH2
O
HN
H2N NH2
NH3
HN
H2N NH2
HN
H2N NH2
O
O HO
O
OH
O OOC
N
H
H
N N
H
O
O
O
O
H
N N
H
H
N N
O
O
O
O
OH
O OOC
OO
OH
O
NH
N
H O
H
N
O
N
H
O
O
H
N NH2
O
NH3
H3N
NH3
a)
b)
	   60	  
 
 
 
Figure 3.3 Structures of protectide-kinase substrate full-length reporter peptides. a) 
MP4B with the protectide, PEG spacer, and kinase substrate regions labeled. b) SMP4B 
c) MD-PEG4-Abl. Phosphorylatable residues are highlighted in red. 
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C.  Results and Discussion 
 
i. Secondary structure characterization of PKB reporter peptides 
 
The FPKB peptide, a substrate for phosphorylation by PKB previously reported by 
Kunkel et al. and Proctor et al., was protected with theMirror and ScramMirror 
protectides (Figure 3.1, Table 3.2).   The secondary structure of the PKB peptide, MP4B 
peptide and the SMP4B peptide was determined by circular dichroism (CD).   The CD 
spectrum of the FPKB peptide showed a minimum near 195 nm confirming that this 
peptide was indeed unstructured, and thus susceptible to rapid degradation by cytosolic 
proteases (Figure 3.2).   The spectrum of the MP4B (Mirror-(PEG2)2-FPKB) reporter 
peptide was very similar to that of the Mirror protectide (Chapter II, Figure 2.8) with a 
maximum near 215 nm, characteristic of β-sheet confirmation.  The peak near 230 nm 
can be attributed to Trp-Trp interactions.  The peaks present in the MP4B CD spectrum 
are more shallow that those of the Mirror protectide only spectrum (Chapter II, Figure 
2.8).   This could mean that there is some terminal fraying caused by the C-terminal 
extension.  However, since the CD spectra were reported using mean residue ellipticity 
(MRE, θ), and MP4B has twice as many residues as Mirror, the degree of folding of the 
protectide is likely very similar in the presence or absence of substrate.  The CD spectrum 
of the SMP4B (Scrambled Mirror- (PEG2)2-PKB) reporter peptide is quite interesting.  
Unexpectedly, it doesn’t display the characteristic random coil maximum peak near 195 
nm as was seen in the Scrambled Mirror peptide spectrum (Chapter II, Figure 2.8).  It 
appears as though a mixture of conformations may be present.   There is a shallow 
minimum near 190 nm that could be due to the C-terminal portion of the reporter which 
lacks secondary structure on its own, though this peak is slightly blue-shifted in 
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comparison to the FPKB peptide CD spectrum.  The broad peak between 200 nm and 
205 nm could be due to the random coil confirmation of the Scrambled Mirror peptide 
alone, although this peak is slightly red shifted (Chapter II, Figure 2.9).  Ironically, there 
is a maximum peak near 215 nm indicative of a β-hairpin conformation.  The C-terminal 
amino acids of the ScramMirror portion of the full-length reporter are Pro-Gly.  
Placement of this reverse turn inducing sequence at the C-terminus of ScramMirror as 
opposed to in the middle of the sequence (like in the Mirror protectide) resulted in a 
random coil confirmation.  However, the Pro-Gly sequence is not at the C-terminus of the 
SMP4B peptide but in the middle, followed by a flexible PEG spacer that could form a 
long loop, making it possible for the reporter fold back on itself.  If this is the case, the 
contacts are likely to be weak given that the two strands have opposite stereochemistry 
and were not designed to have optimal cross-strand noncovalent interactions.  To 
accurately determine the lack or presence of secondary structure in the SMP4B reporter 
peptide, further investigation by NMR is required.  Further structural characterization 
was not deemed necessary for our purposes but may be considered in the future. 
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Figure 3.4 Circular dichroism spectra of the FPKB, the MP4Band the SMP4 reporter 
peptides. Experiments were done at 40 µM peptide concentration in 10 mM sodium 
phosphate buffer, pH 8 at 25°C.  The FPKB (blue) peptide has a random coil 
conformation shown by the minimum near 195 nm. The MP4B (green) peptide displays 
β-sheet character indicated by a maximum near 215 nm.  The local maximum near 230 
nm is due to Trp-Trp interactions.  The SMP4B (red) peptide has an unconfirmed but 
likely mixed conformation.   
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ii. Investigation of protectide-PKB substrate reporter in vitro by pronase E 
The first protectide-substrate reporter to be tested for resistance to proteolytic 
degradation was the MP4B reporter peptide.  This peptide was incubated in the presence 
of pronase E from 24-hours and was quenched and monitored by analytical RP-HPLC at 
different time points.  The ScramOWOWO peptide was also incubated with pronase E 
in this assay to serve as a known positive degradation control.  The analytical RP-HPLC 
chromatograms of the assay are shown below in Figures 3.5 and 3.6.   Within 5 mins at 
least one degradation product was seen in the chromatogram of the MP4Breporter 
peptide.  Over the course of 24 hours, a few more peaks were seen at different time 
points.  Without mass spectrometry confirmation, it was speculated that the two major 
degradation products corresponded to hydrolysis of the peptide bond between the PEG 
spacer and the protectide and possibly cleavage of the bond between the PEG spacer and 
the substrate.  It is also possible that the Pro-Gly peptide bond in the protectide portion of 
each could have be hydrolyzed. Mass spectrometry is needed to identify the degradation 
products present.  Currently, we are using MALDI mass spectrometry to correctly 
identify the fragments.  Knowledge of the pronase E generated degradation products will 
be useful in the redesign strategy for making more resistant substrates.  These results did 
not deter us from examining Mirrror-protected substrates in cell lysates because pronase 
E contains exopeptidases and endopeptidase that are not present in the cytosol and in 
whole cell lysates.     
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Figure 3.5 Degradation of the ScramOWOWO peptide in the presence of pronase E.  
Peptide concentration was 100 µM and degradation was observed over 15 minutes.  Time 
points were quenched with acetic acid (peak at 2 minutes) and determination of intact 
peptide remaining was done using analytical RP-HPLC, monitoring at 220 nm. 
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Figure 3.6 Degradation of the MP4B peptide in the presence of pronase E.  Peptide 
concentration was 100 µM and degradation was observed over 24-hours.  Time points 
were quenched with acetic acid and determination of intact peptide remaining was done 
using analytical RP-HPLC, monitoring at 220 nm. 
iii. Investigation of SMP4B and MP4B in OPM-2 cell lysates 
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Next MP4B and SMP4B were incubated with OPM-2 cell lysates.  OPM-2 cells are a 
multiple myeloma cell line that we used for several assays as a model system for the 
optimization of the protectides for intracellular assays.  The protectide-PKB reporter 
peptides were incubated with OPM-2 whole cell lysates for 2 hours, quenching at various 
time points and analyzed to determine the amount of intact peptide remaining over the 
time course. The results of this cell lysate degradation assay were analyzed by capillary 
electrophoresis coupled with laser-induced fluorescence (CE-LIF).  There were three 
advantages to using CE-LIF as opposed to analytical RP-HPLC: 1)fluorescence 
detection,  2) tunable separation of the fragments, and 3)less sample required for analysis.   
Fluorescence detection allows for only peptides with FAM conjugated to be detected, 
therefore there was no signal interference from other molecules present in the cell lysates.   
Optimizing CE electrophoretic separation is easier, faster, and requires far less solvent 
than the optimization of analytical RP-HPLC solvent systems.  Finally, limit of detection 
of CE-LIF is much lower (subnanomolar) than that of analytical RP-HPLC (low 
micromolar), which is required with single-cell analysis and preferred with cell lysates as 
well.  Cleavage of reporter peptides was observed in the early time points (data not 
shown).   Currently, we are optimizing CE electrophoretic buffer conditions to separate 
all of the degradation products to allow us to calculate the amount of intact peptide 
remaining.  We are also utilizing MALDI mass spectrometry to determine which peptide 
bonds of the full-length reporter peptides are most susceptible to hydrolysis.   Once 
optimal separation conditions are found and CE and the fragments are confirmed by 
MALDI mass spectrometry, the reporters will be redesigned and resynthesized to 
increase the resistance of the vulnerable bonds.   
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It must be noted that these lysates were generated using the mammalian-protein 
extraction reagent (MPER).  It was later determined after the assay that this reagent 
possibly contained protease inhibitors and therefore an alternative lysis protocol was used 
in subsequent studies.   
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iv. Investigation of protectide-Abl kinase reporter peptide 
Work done by Dr. Imola Zigoneanu, a post-doctoral fellow in Allbritton Group, 
Department of Chemistry, University of North Carolina at Chapel Hill on protectides 
developed by Kaiulani Houston. 
 
To further investigate the versatility the protectide strategy, an Abl kinase substrate 
peptide was synthesized with a PEG4 spacer and the Mirror protectide attached (MD-
PEG4-Abl).  First the MD-PEG4-Abl reporter was incubated with purified Abl kinase in 
vitro in the presence of ATP.  Phosphorylation of the protectide-reporter was observed by 
CE-LIF (Figure 3.7).  Complete phosphorylation of MD-PEG4-Abl was not observed 
however.  This may be due the PEG4 spacer not being long enough to prevent steric 
hindrance during phosphorylation or it may be due to efficacy of the substrate.  The 
degree of phosphorylation of the Abl peptide alone was not observed at the time under 
the same conditions, therefore a comparison could not be made.  Though further 
optimization is required, Figure 3.7 gives strong evidence that the protectide-substrate 
can be designed to maintain its efficacy as a kinase substrate.   
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Figure 3.7  Phosphorylation of the MD-PEG4-Abl reporter peptide by Abl kinase.  
Experiments done at 37°C with 30 µM peptide concentration and 30 µM enzyme 
concentration for 30 minutes.  Results observed by CE-LIF using 150 mM sodium 
phosphate, 5 mM SDC, pH 7.3 as the electrophoretic buffer in a 50 µm capillary. 
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To determine if the incorporation of protectide increased the stability of the Abl 
kinase reporter in the presence of cellular proteases, the MD-PEG4-Abl peptide was 
incubated with Ba/F3 BCR-Abl cells lysates .  The Ba/F3 BCR-Abl cell line are murine 
pro-B cells that express the oncogene BCR-Abl kinase whose constitutive activity is 
responsible for most cases of CML. The stability of the protectide-Abl peptide reporter 
was monitored at various time points between 0-30 minutes (Figure 3.8).  The Abl 
peptide alone degraded quickly in lysates with a half-life around 3 minutes.  The addition 
of the Mirror protectide and the PEG4 spacer positively impacted the stability of the Abl 
kinase reporter.  The half-life of the MD-PEG4-Abl reporter was around 20 minutes, 
showing approximately a 7-fold improvement in stability.  We believe that this increase 
in stability is mostly attributed to the protectide rather than the PEG4 spacer as the 
protectide provided the bulkiness needed to hinder entrance into the catalytic cleft of the 
proteases. We therefore conclude that the addition of a protectide to the N-terminus of a 
kinase substrate is a promising method for the generation of protease resistant reporters 
of enzymatic activity in vitro. 
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Figure 3.8  Assessment of the stability of the Abl kinase reporter peptide (6FAM-Abl, 
pink) and the MD-PEG4-Abl reporter peptide (blue) in the presence of Ba/F3 BCR-Abl 
cell lysates.  The y-axis represents the % of intact peptide remaining.  Experiments were 
done at a 1 µM peptide concentration in 3mg/mL lysate at 37°C. Results observed by CE-
LIF using 150 mM sodium phosphate, 5 mM SDC, pH 7.3 as the electrophoretic buffer in 
a 50 µm capillary. 
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D. Conclusions 
Above we described our efforts to extend the lifetimes of kinase substrates by 
attaching a β-hairpin D-amino acid protectide to their N-termini.  When the protectide-
PKB substrate was incubated with nonspecific proteases from pronase E degradation was 
seen within 5 minutes.  This was not unexpected given that exopeptidases that are not 
found in the cytosols of immune cells were present in the pronase E cocktail. Dr. Imola 
Zigoneanu in the Allbritton Lab synthesized a protectide-Abl kinase reporters.  When 
incubated with cell lysates degradation was seen within 15 minutes though the protected 
substrate did last longer in the presence of cell lysates than the unprotected substrate . 
Based on these results, we conclude that while the Mirror protectide is protease-
resistant, it does not effectively protect C-terminal substrates from degradation.  One 
possible explanation for our observations is that while the protectides are considered 
well-folded, there is a dynamic equilibrium between a folded and unstructured state.  It is 
possible that the protectide-substrates can be woven into the catalytic clefts of proteases 
while the protectide was sampling an unfolded state.  Another possibility is that the lysate 
endopeptidases began hydrolysis at the C-terminal portion of the protectide reporters 
since there was no negative charge from a C-terminal carboxylate at the end of the 
reporter peptide to deter catalytic cleft entrance.   Efforts to attach cyclized protectides to 
kinase substrates are underway.  Also, we are exploring ways to incorporate N-terminal 
and C-terminal negative charges in the sequences of the protectide-kinase reporters to 
minimize threading into the catalytic sites of proteases. 
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E. Ongoing work 
The kinase activity reporters described above were synthesized by SPPS in a linear 
fashion generating the full-length protected substrate at the end of synthesis.    Linear 
synthesis of the combined protectide, PEG linker, and PKB substrate peptide was both 
synthetically challenging and hard to purify.  In addition, the protectide would have 
broader applications if libraries of protectides and substrates were synthesized separately 
and stored, then conjugated by a quick one-step reaction at the time of the assay.  To 
circumvent the problematic linear synthesis of the protected PKB substrates and to 
expand the application of the protectide, the protectides and the PEG2-PKB substrates 
peptides are being synthesized individually but are functionalized for click chemistry 
(Scheme 3.1).  Prior attempts do to a fully solution phase click chemistry were 
unsuccessful. However, solid phase copper-catalyzed click chemistry, with the substrate 
peptide bearing the azide immobilized on resin and the protecting group bearing an 
alkyne free in solution will likely be more successful.  Currently, we are attempting to 
synthesize full-length protected PKB activity reporters by adding a solution containing 
protectide and a copper source to a PEG2-PKB substrate peptide with an azidolysine as 
the N-terminal residue, which is immobilized on CLEAR-Amide beads and allowing 
them to mix for several hours.  The protected substrate will then be cleaved from the 
resin and purified if necessary by RP-HPLC. The ultimate goal is to be able to quickly 
protect, inject, and detect multiple enzymatic activities inside a patient cells using these 
protectide reporter peptides coupled with the power of single cell CE-LIF.    Reaching 
this goal would allow us to quickly screen for enzymatic activity prior to treatment to 
determine what available enzyme inhibitor would be post beneficial to a patient.    Such a 
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multi-dimensional assay would be beneficial post-treatment as well for the determination 
of how effectively the inhibitors are blocking enzymatic activity in patient cells and 
would allow the early detection of therapy-resistant cell populations.    Optimization of 
this assay would expand capability of detecting enzymatic activity in any population of 
diseased cells that are diagnosed or observed ex vivo. 
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Scheme 3.1 Using click chemistry to conjugate kinase substrates to cyclized protectides.  
A propargyl glycine residue on the cyclized protectide is reacted with an azidolysine 
residue on the kinase substrate immobilized on resin, via a copper (I)-catalyzed azide-
alkyne cycloaddition (CuAAC, click chemistry).  The protectide-substrate is then 
cleavage from the resin. 
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F. Experimental 
Peptide Synthesis and Purification 
 Peptides were synthesized using manual or automated standard solid phase 
peptide synthesis (Thuramed Peptide Synthesizer, CEM Liberty1 Microwave Peptide 
Synthesizer) using Fmoc protected amino acids on 0.06-0.08 mmol of CLEAR Amide 
resin from Peptide International.   Four equivalents of standard amino acids were used for 
each peptide synthesis while 1.5-4 equivalents of noncanonical amino acids and 
fluorophores were used.  All peptides were acetylated at the N-terminus by treating the 
resin with 5% acetic anhydride and 6% 2,6-lutidine in 5 mL of DMF bubbling with N2 for 
40 minutes.   5(6)-Carboxyfluorescein (FAM) was coupled to the ε-NH of lysine or the δ-
NH of ornithine at the i+4 position of the beta-hairpins or the centrally located amino 
acids of the scrambled sequences.  The sidechains of these amino acids were orthogonally 
protected with an allyloxycarbonyl group (N-Alloc) or with 1-(4,4-dimethyl-2,6-
dioxocyclohex-1-ylidene-3-methylbutyl (N-ivDde).   Alloc removal was done based on 
the protocol published by Pazos et al.15 The removal of ivDde from the sidechain of 
lysine or ornithine was accomplished by treating the peptide resin 3 x 2 mins with 20 mL 
of 2% hydrazine monohydrate in DMF bubbling with N2 followed by washing with 
DMF, MeOH, DCM. Following deprotection, FAM was coupled using 2-4 equivalents of 
FAM, 5 equivalents of PyBOP/HOBt and 8 equivalents of DIPEA in 5 mL of DMF and 
allowed to bubble with N2 for 4-8 hours.   
_________________________ 
15Pazos, E.; Jiménez-Balsa, A.; Maszareñas, J.L.;  Vázquez, M.E. Chem Sci2011, 2, 
1984-87 
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Double coupling was sometimes required.  Kaiser testing was done after the capping, 
deprotection and coupling steps.  Peptides without cysteine were cleaved from the resin 
in 9.5:2.5:2.5 trifluoroacetic acid (TFA), TIPS and water respectively for 3-4 hours. 
Peptides containing cysteine were cleaved using 9.4:2.5:2.5:1 TFA, EDT, water and TIPS 
respectively for 3-4 hours. The TFA was evaporated and the cleaved peptides were 
precipitated using cold ethyl ether and extracted with water.  Extracted peptides were 
lyophilized and then purified using semi-preparative RP-HPLC on a Vydac C18 semi-
preparative column with a gradient from ‘0 to 100% B’ in 45-120 minutes.  Solvent A 
was 95% water, 5% acetonitrile and 0.1% TFA and Solvent B was made of 95% 
acetonitrile, 5% water and 0.1% TFA.  Purified peptides were lyophilized and their 
synthesis and purity confirmed by ESI-TOF or MALDI-TOF using 2,5-dihydroxybenzoic 
acid matrix. 
 
Peptide Concentration Determination 
 
UV/Vis was used for the concentration determination of each peptide in 10 mM sodium 
phosphate buffer (100 mM NaCl, pH 7.48 for protease degradation studies) pH 8 using 
FAM abosorbance at 492 nm, ε492 = 78,000 M-1 cm-1, for peptides with FAM or by 6 M 
guanidinium chloride denaturation and tryptophan absorbance at 280 nm ε280 = 5690 M-
1cm-1  for peptides without FAM. 
 
Circular Dichroism Spectroscopy  
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CD spectroscopy data was collected using an Applied Photophysics Chiroscan Circular 
Dicroism  Spectrophotometer.  Spectra were generated at 25 °C with a wavelength scan 
260 nm to 185 nm, with 0.5 second scanning in a 0.1 cm cell.  Peptide concentrations of 
40 µM in 10mM sodium phosphate buffer, pH 8.0 (peptides with FAM) or pH 7.4 
(peptides without FAM) were used. 
 
Peptidase Concentration Determination 
 
Pronase E enzymes from Streptomyces griseus were purchased as a lyophilized powder 
from Sigma-Aldrich (EC 3.4.24.31). Stocks were made by bringing up 5 mg of enzyme in 
15 mL of 10 mM sodium phosphate buffer, 100 mM NaCl pH 7.48 (0.33 mg/mL). 1 ml 
aliquots were stored in the -80° C freezer for future use.  As 7 µL of enzyme stock in 1.3 
mL of peptide solution completely digested the ScramOWOWO peptide in 15 minutes, 
this was the volume of enzyme used in all protease studies. 
 
Peptide Degradation by Pronase E  
 
The enzymatic proteolysis procedure was adapted from Cline and Waters.13c  The 
reaction was initiated by the addition of 7 µL of pronase E stock solution to 1.293 mL 
solution of 100 µM peptide in 10 mM sodium phosphate buffer, 100 mM NaCl pH 7.5 at 
37°C .   75 µL aliquots were taken at 0, 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 
720, 1080, 1440 minutes and quenched with 10 µL of acetic acid and 15 µL of buffer 
generating a total volume of 100 µL.  25 µL of each quenched sample was injected on the 
analytical RP-HPLC  (Waters) and the fraction of peptide remaining at each time point 
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was determined based on the absorbance of each peptide at 214 nm and/or 280 nm.  Peak 
integrations were done using Empower Pro 2 software. The acetic acid peak was used as 
an internal standard.  The fraction of full-length peptide at each time point was 
determined by dividing the total peak area of the full-length peptide at each time point by 
the area of the acetic acid peak.  This number was divided by the corresponding value of 
the zero time point.   
 
Abl Kinase Phosphorylation Assay 
 
Phosphorylation assays were conducted by mixing 4 µL of 10X assay buffer (500 mM 
Tris pH 7.5, 5 mM MnCl2 and 25 mM MgCl2), 4 µL of 10X DTT (20 mM DTT in water), 
4 µL of 10X Abl kinase (3 ng/µL) in 50 mM Tris [pH 7.5], 100 mM NaCl, 0.1 mM 
EDTA, 5 mM DTT, 50% (v/v) glycerol, 14 µL of water and 12 µL of 100 µM peptide in 
a reaction vessel.  The reaction was initiated with the addition of 2 µL of 20 mM ATP 
and the reactions were incubated at 30°C.  The reactions were quenched at 90°C for 4 
minutes.  Samples were stored at -20°C until time of analysis. 
 
Ba/F3 BCR-ABL Lysate Degradation Assay 
 
Ba/F3 BCR-Abl cells cultured in T-25 or T-75 culture flasks combined centrifuged at 0.8 
rcf for 2.5 minutes.  Media was discarded and the cells were washed twice with 10 ml of 
1X PBS (137 mM NaCl, 27 mM KCl, 10 mM Na2HPO4, 1.75 mM KH2PO4, pH 7.4).  
Supernatant was discarded and the combined pellet was resuspended in 50-200 µL of 1X 
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PBS.  Cells were submerged in liquid nitrogen for 1 min and immediately thawed in a 
37°C water bath.  The freeze-thaw cycle was repeated 2 times (a total of 3 cycles).  Cells 
were centrifuged at 14,000 rcf at 4°C for 4 minutes.  The supernatant was removed and 
kept at 4°C for the duration of the experiment.  The pellet was discarded.  Lysates were 
used within 4 hours of generation.  Total protein concentration in the Ba/F3 BCR-Abl 
lysate was determined by mixing 30 µL of lysate (diluted 1:1000 in PBS) with 10 µL of 
fluorescamine (3 mg/mL) and allowing them to react for 5 minutes at room temperature 
in the dark.  Immediately after, the fluorescence was measured using M5 Molecular 
Devices Spectrometer ( 475 nm) and compared with that of BSA protein standards mixed 
with fluorescamine.  A 200- 400 µL solution was made containing 3 mg/mL final Ba/F3 
BCR-Abl lysate concentration and 10 uM final peptide concentration.  The peptide/lysate 
solutions were incubated at 37 °C and aliquots of 20-40 µL were removed at various 
times points (0, 1, 2, 3, 5, 10, 15, 30 minutes) and quenched with equal amounts of 200 
mM HCl.  Aliquots were frozen and stored at -20°C until time of analysis. 
 
Capillary Electrophoresis 
 
Detection of peptide phosphorylation in vitro and peptide degradation in Ba/F3 BCR-Abl 
lyastes was achieved by laser-induced detection (LIF, 488 nm) during capillary 
electrophoresis (ProteomeLab PA800, Beckman Coulter, Fullerton, CA).  Fused-silica 
capillaries (30 or µm 50 µm inner diameter, 360 µm outer diameter, Polymicro 
Technologies, Phoenix, Az) were used with an effective length of 20 cm and a total 
length of 30 cm. Capillaries were preconditioned with 1 NaOH for 12 h, DI H2O for 1 h, 
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0.1 M HCl for 6 h followed by DI H2O for 12 h.  Between each sample run, a pressure of 
20 psi was applied at the capillary inlet allowing the capillaries to be rinsed with 1 NaOH 
for 2 min, DI H2O for 2 min, and with electrophoretic buffer for 2 min.  Quenched 
samples from the Abl kinase phosphorylation assay  Ba/F3 BCR-Abl lysate degradation 
assay were separated using 150 mM sodium phosphate, 5 mM SDC, pH 7.3 as the 
electrophoretic buffer. Samples were loaded into the capillary hydrodynamically by 
applying a pressure of 0.5 psi at the inlet for 5 sec.  A negative voltage was then applied 
to initiate electrophoresis.  Electrophoresis was done for 20 mins with a field strength of 
12 kV cm-1.  Results were analyzed using 32 Karat, version 8.0 (Beckman Coulter, 
Fullerman, CA). 
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Chapter IV 
 
β-HAIRPIN PEPTIDES AS SUBTRATES AND REPORTERS OF UBIQUITIN 
PROTEASOME SYSTEM ACTIVITY 
Reproduced in part with permission from Houston, K.M.; Melvin, A.T.; Woss, G.S.; 
Waters, M.L.; Allbritton, N.L., Manuscript in preparation. 
 
A. Background 
 
Degradation of proteins in the cell 
 
 Regulation of cellular homeostasis, migration, and division is accomplished via a 
continuous cycle of protein expression, post-translational modification and degradation.1  
Degradation of misfolded proteins or inactivated proteins is accomplished by two major 
pathways; proteasomal degradation and lysosomal degradation. Targeting a protein for 
either pathway usually involves post-translational polyubiquitination at a lysine sidechain 
of the target protein, though modification at cysteine, serine, or threonine sidechains has 
been reported.1 Ubiquitin is a small 76-amino acid ( 8.5 kDa) globular protein whose 
attachment and removal from substrate proteins is accomplished by over a thousand 
enzymes collectively known as the Ubiquitin-Proteasome System (UPS, Figure 4.1).2 
________________________________ 
1Amm, I.; Sommer, T.; Wolf, D.H. Biochem et Biophys Acta2014, 1843, 182-96. 
2Eletr, Z.M.; Wilkinson, K.D. Biochem et Biophys Acta2014, 1843, 114-128.   
3Melvin, A.T.; Woss, G.S.; Park, J.H.; Waters, M.L.; Allbritton, N.L. Cell Biochem 
Biophys, 2013, 67, 75-89. 
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Figure 4.1 The Ubiquitin Proteasome System.3 The enzyme cascade responsible for the 
transfer of ubiquitin and ubiquitin-like proteins (UbLs) to substrates targeted for 
proteasomal degradation.  Ubiquitin (or UbL) is activated by an E1 enzyme and 
transferred to an E2 enzyme.  The ubiquitin conjugated E2 enzyme binds to one of two 
types of E3 ligases (HECT or RING), which mediate the transfer of one or more ubiquitin 
moieties to the protein substrate.  The ubiquitinated protein is trafficked to the 
proteasome and just before protein degradation, the ubiquitin moieties are removed by 
DUBs bound to the 19S cap of the proteasome.  Ubiquitin is recycled and the protein 
substrate is hydrolyzed by the proteasome into oligopeptide fragments.  
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Polyubiquitination occurs through the formation of an isopeptide bond between the C-
terminal carboxylate of an incoming ubiquitin and a lysine sidechain of the substrate-
conjugated ubiquitin.  Ubiquitin has seven Lys residues allowing for linear and branched 
polyubiquitination and multiple sites of monoubiquitination, each signaling for a different 
substrate protein fate.  A linear chain of four or more ubiquitins, linked at Lys48 on 
ubiquitin, is the signal most commonly associated with proteasomal degradation.4 
 Three families of enzymes are responsible for transferring ubiquitin onto substrate 
proteins.   The E1 ubiquitin activating enzyme, adenylates the C-terminus of ubiquitin via 
ATP hydrolysis allowing it to react with an E2 ubiquitin conjugating enzyme forming, a 
thioester intermediate bond between the E2 and ubiquitin. The final class of enzymes, the 
E3 ubiquitin ligases, bind to the E2 enzyme and some bind ubiquitin and either serve as a 
scaffold or directly catalyze the condensation of the C-terminal carboxylate of ubiquitin 
with Lys ε-amino group of the substrate protein,forming an isopeptide bond.  There are 
two types of E3 ligases, HECT family E3 ligases and RING family E3 ligases which 
mediate the indirect and direct transfer of ubiquitin respectively.2   Just before 
degradation by the proteasome, the ubiquitin chain can be removed via hydrolysis of the 
isopeptide bond by a family of proteases known as deubiquitinating enzymes 
(DUBs).2The 26S proteasome is a large protein complex made of the 19S regulatory unit 
and the 20S catalytic core.4  The regulatory unit (RP) serves as a cap and regulates access 
of targeted proteins to the catalytic pore.   
_____________________ 
4Schmidt, M.; Finley, D. Biochem et Biophys Acta2014, 1843, 13-25. 
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The 20S unit harbors three proteolysis chambers, one with chymotrypsin-like activity 
(cleaving after hydrophobic residues), one with tryspin-like activity (cleaving after basic 
residues), and one with caspase-like activity (cleaving after acidic residues).4   Along 
with the 26S proteasome, a small population of immunoproteasomes have been reported, 
which are responsible for digesting proteins into peptide fragments within immune cells 
for antigen presentation and recognition by neighboring immune cells.4  Once proteins 
are digested into oligopeptides by any type of proteasome, the oligopeptides are further 
digested by cytosolic peptidases into smaller fragments for MHC-class presentation (to 
initiate and immune response) or into individual amino acids which are recycled for 
cellular anabolism.   It is important to note that the UPS is responsible for far more than 
protein degradation within the cell.  Protein ubiquitination is part cell cycle regulation, 
embryonic development and regulating immune responses.5  The UPS machinery also 
installs other ubiquitin-like proteins (UbLs) such as SUMO (small-ubiquitin-like 
modifier, 12 kDa) and NEDD8 (6 kDa), onto substrate proteins to dictate a particular 
cellular fate such as apoptosis or cell cycle progression.6  These latter functions of the 
UPS are beyond the scope of this work and will not be discussed further here. 
______________________ 
5Myung, J.; Kim, K.B.; Crews, C.M. Med Res Rev, 2001, 21, 245-73. 
 
6(a) Bohren, K.M.; Nadkarni, V.; Song, J.H.; Gabbay, K.H.; Owerbach, D. J Biol Chem,  
2004, 279, 27233-8 (b)Gong, L.; Yeh, E.T.H, J Biol Chem, 1999, 274, 12036-42. 
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Clinical Relevance of UPS Activity 
 Regulating proteasome expression and function as a way of treating cancer, 
neurodegenerative diseases, and cardiac disease has become a popular area of drug 
discovery research4 The success of the FDA approved drug bortezomib (Velcade®), a 
reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in the 
treatment of refractory multiple myeloma, inspired research and exploration of the UPS 
that could one day rival provide as many druggable target as that of the 
kinase/phosphatase proteome.7 Carfilzomib (Kryprolis), a more potent irreversible 
inhibitor of the chymotrypsin-like activity of the 26S proteasome, has recently been 
approved for treatment of bortezomib-resistant multiple myeloma patients.8 Carfilzomib 
also inhibits the immunoproteasome giving an added advantage over bortezomib.8  In 
neurodegenerative diseases and cardiac disease, increasing proteasome expression and 
activity rather than inhibition of activity, is the objective of treatment.  There are eight 
known E1 enzymes, approximately forty E2 enzymes, and several hundred identified E3 
enzymes in addition to nearly eighty DUBs. The success of proteasome inhibitors has 
driven the development of drugs that inhibit the catalytic activity of E1, E2 and DUBs 
enzymes and drugs that disrupt E3 ligase protein-protein interactions.8 Of particular 
interest are inhibitors of murine double minute 2 homolog, MDM2 (or HDM2, the human 
counterpart), the E3 ligases responsible for the ubiquitination of the transcription factor 
p53.    
______________________ 
7Cohen, P.; Tcherpakov, M. Cell2010, 143,686-93. 
8Mattern, M.R.; Wu, J.; Nicholson, B. Biochem et Biophys Acta, 2012, 1823, 2014-21. 
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 Famously, p53 is referred to as the guardian of the genome because it serves as a tumor 
suppressor by employing cell cycle arrest and apoptosis in the presence of oncogenic 
protein expression.9  Functional wild-type p53 is lacking in more than 50% of cancer 
patients, making restoration of its activity one of the most highly sought after goals in 
cancer therapeutic research.9   It is believed that tumor cells target p53 to the proteasome 
through ubiquitination of p53 by the E3 ligase MDM2 (or HDM2) leading to the 
degradation of p53 by the proteasome, effectively preventing tumor cell apoptosis. 
Thalidomide, originally prescribed in the 1950s to treat morning sickness before it was 
linked to birth defects, is now used to treat leprosy and multiple myeloma.  It was 
recently reported that thalidomide disrupts protein-protein interactions of an E3 ligase 
complex by binding the protein cereblon, which modulates the substrate specificity of the 
Cul4A-Roc-DBB1 E3 ligase complex.10  These are just two of several examples of how 
cancer therapy regiments are being expanded to include drugs that disrupt UPS activity.  
Inhibition of DUB activity is also being explored as a way to promote proteasome-
mediated proteolysis in diseases where there is low activity. 2  The development of UPS 
modulators for clinical use necessitates the development of diagnostic tools that can 
detect activity of the UPS ex vivo. 
_____________________ 
9 (a) Hoe, K.K.; Verma, C.S.; Lane, D.P. Nat Rev Drug Discovery.2014, 13, 217-236. (b) 
Lane, D.P. Nature1992, 358, 15-6. 
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Detection of UPS activity using peptides synthesized by solid phase peptide synthesis 
 The expression of UPS proteins can be detected in cell lysates using antibody-
based assays.  The most commonly employed methods of detecting UPS activity involves 
genetically engineered substrates that are ubiquitinated within the cells, inducing a 
change in fluorescence that can be detected.3  While gene expression products have 
provided significant insight about regulation of proteasome activity,  they are impractical 
when evaluating UPS activity in patient tumor cells.  Kumar et al. synthesized 
ubiquitinated peptides using solid phase peptide synthesis (SPPS) and native chemical 
ligation and used these constructs to evaluate DUB activity in vitro.11 UPS activity has 
been evaluated using short fluorescently tagged peptide substrates of  UPS enzymes also 
synthesized SPPS.12  The sequences of the reporter peptides were derived from 
intracellular proteins whose activity is controlled by ubiquitin-dependent degradation by 
the 26S proteasome.  These peptides contained a degradation signal or degron, which was 
recognized by E3 ligases as a substrate for ubiquitination.  
 
_____________________ 
10Ito, T.; Ando, H.; Handa, H., Cell Mol Life Sci, 2011, 68, 1569-79. 
 
11Kumar, K.S.A.; Spasser, L.; Ohayon, S.; Erlich, L.A.; Brik A. Bioconjugate Chem2011, 
22, 137-43. 
 
12Melvin, A.T.;Woss, G.S.,;Park, J.H.; Dumberger, L.D.; Waters, M.L.,; Allbritton, N.L. 
PLoS ONE, 2013, 8, e78082. 
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Degrons recognized by the UPS 
 Degrons are structural motifs on proteins recognized by cytosolic peptidases and 
UPS-associated degradation complexes that trigger the degradation of that protein.13 One 
stipulation is that these sequences must be portable, meaning when attached to any 
substrate peptide these degrons target the peptide for degradation within the cells. UPS-
specific degrons include N-terminal degrons or N-degrons, phosphodegrons, oxygen-
dependent degrons, and ER-associated degrons.  A N-degron is an free amino terminus 
bearing a specific amino acid often exposed after a cleavage event, that is recognized and 
bound by a specific E3 ligase leading to the ubiquitination and degradation of that 
particular protein.13   The N-end rule pathway, first characterized by Varshavsky and 
coworkers, showed that the identity of the N-terminal amino acid determines the lifetime 
of the protein in the cell. Amino acids such as Arg, Lys, or His residues at the N-terminus 
of a protein in the cell result in a half-life of ~2 minutes, while newly synthesized 
proteins have a stabilizing Met residue at the N-terminus.14   Phosphodegrons are specific 
amino acid sequences within a protein that when phosphorylated at Ser or Thr residues 
are subsequently recognized by a specific E3 ligase, such as SCFβTrCP, to promote 
ubiquitination.13   Protein phosphorylation paired with ubiquitination of cytosolic and 
nuclear proteins are important for cell cycle progression, leading to the activation of cell 
growth signaling proteins and the degradation of their inhibitory regulators.13-14 
_________________________ 
13Ravid, T.; Hochstrasser, M. Nat Rev Mol Cell Bio, 2008, 9, 679-90. 
14 a) Varshavsky,A. Proc. Natl. Acad. Sci. Biochem, 1996, 93, 12142-49 b) Varshavsky, 
A. Prot Sci,2011, 20, 1298-1345. 
 
 
	   91	  
Oxygen-dependent degrons are unique in that they are proteins recognized and targeted 
for degradations in oxygenated cellular conditions.13 The most common oxygen-
dependent degron is the protein hypoxia-inducible factor-1 (HIF1) transcription factor 
complex, which is active in hypoxic but its HIF-1α subunit is ubiquitinated and degraded 
by the proteasome after cellular molecular oxygen concentrations increase.13 
Endoplasmic reticulum (ER) degrons are thought to be hydrophobic patches on proteins 
only exposed when they are misfolded.  Such regions are recognized by chaperones in the 
ER, prompting the export, ubiquitination, and degradation of these proteins.13  It has been 
reported that the portable degron itself may not sufficient for degradation by the 
proteasome.   
The aforementioned degrons are sufficient for substrate ubiquitination but conjugated 
to short peptides would not ensure proteasomal degradation.  The peptide or protein must 
be of certain chain length and lack secondary or tertiary structure C-terminal to the 
ubiquitination site to be a substrate for proteasome-mediated degradation.  Degron-based 
peptides with these structural features capable of being ubiquitinated by E3 ligases and 
degraded by the proteasome are called two-component degrons.16  The N-terminal portion 
is recognized and ubiquitinated by the corresponding E1, E2, and E3 enzymes while the 
unstructured C-terminal portion is bound by the 19S cap of the 26S proteasome directed 
into the 20S catalytic cleft, initiating degradation.   
_________________________ 
16(a)Alfassy, O.S; Cohen, I. Reiss, Y.; Tirosh, B.; Ravid, T. J Biol Chem, 2013, 288, 
12645-53. (b) Inobe, T.; Fishbain, S.; Prakash, S.; Matouschek, A.  Nat Chem Biol, 2011, 
7, 161-7. 
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It is presumed that the N-terminal portion of the two-component degron is 
deubiquitinated and unfolded (if it has a higher order of structure) and guided into the 
catalytic cleft as well.  Verhoef et al. found that an additional 25 amino acids on the 
substrate peptide C-terminal to the ubiquitination site was required for proteasomal 
degradation in both mammalian cells and yeast.17  Shabek et al. demonstrated that 
monoubiquitination was sufficient for ubiquitinated substrates shorter than 150 residues 
but proteasomal degradation of longer substrates required polyubiquitination.18 
 Typically, when investigating modification of degrons by the UPS, Lys residues 
within the degron sequence are the sites of modification.   Here we report that a 12-
residue β-hairpin peptide functions as a degron with an Orn rather than Lys as the 
ubiquitination site.  Orn is a noncanonical amino acid lysine analog with one less CH2 
group in its sidechain. We demonstrate that secondary structure of the degron promotes 
its resistance to degradation in cell lysates.  Finally we report preliminary work 
investigating the E3 ligase(s) responsible for the ubiquitination of these novel degrons.  
The work presented here will lay the groundwork for the development of  in vivo UPS 
activity reporters. 
________________________ 
17Verhoef, L.G.G.C.; Heinen, C.; Selivanova, A.; Halff, E.F.; Salomons, F.A.; Dantuma, 
N.P. J Fed Am Soc Exp Biol2009, 23, 123-33. 
 
18Shabek, N.; Herman-Bachinsky, Y.; Buchsbaum, S. Lewinson, O.; Haj-Yahya, H.; 
Hejjaoui, M.; Lahsuel, H.A.; Sommer, T.; Brik, Cienhanover, A. Mol Cell2012, 48, 87-
97. 
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A. Design and Synthesis 
 Seven Orn containing peptides were synthesized using SPPS as described earlier.  
The OWOWOβ-hairpin peptide served as the parent degron and four versions of the 
peptide were made where one or more of the ubiquitinatable Orn residues were replaced 
with an Arg residue to determine the preferential site(s) of ubiquitination .  The 
ScramOWOWO peptide, containing an equal number of Orn residues as OWOWO, 
was synthesized as an unstructured control.  The OWOWO-RRRGpeptide was 
synthesized to increase the protease resistance of the Bonger degron peptide and to serve 
as a two-component degron.12,20  The III-67B peptide was included as a positive control 
for the OPM-2 cell lysate degradation assay as it has previously been shown to degrade 
rapidly in cell lysates.19  The fluorophore 6-carboxyfluorescein (FAM) was covalently 
attached to an Orn sidechain next to the turn sequence or to the N-terminus of all peptides 
investigated for detection.  The sequences of all peptides investigated and discussed in 
this chapter are listed in Table 4.1. 
________________________________  
19Proctor, A.; Wang, Q.; Lawrence, D. S.; Allbritton, N. L. Analyst2012, 137, 3028–38. 
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Table 4.1 Ubiquitinatable degrons and positive control peptidea 
 
Degron Peptide Sequence 
ScramOWOWO Ac-OWVOWIO(FAM)QVOpG-NH2 
OWOWO Ac-OWVOVpGO(FAM)WIOQ- NH2 
OWRWR Ac-OWVRVpGO(FAM)WIRQ- NH2 
RWOWR Ac-RWVOVpGO(FAM)WIRQ- NH2 
RWRWO Ac-RWVRVpGO(FAM)WIOQ- NH2 
RWRWR Ac-RWVRVpGO(FAM)WIRQ- NH2 
III-67B (Control) 19 FAM-GGAYAATKKKKA- NH2  
RRRG FAM-RRRGGGGK-NH2 
OWOWO-RRRG 12,20 Ac-OWVOVpGO(FAM)WIOQ-(PEG)2-RRRGGGGK-NH2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
________________________ 
aIII-67B- BCR-Abl substrate peptide known to degrade rapidly in cell lysates. Residues 
highlighted in blue are potentials sites of ubiquitination. The III-67B was not tested in 
any ubiquitination assays. 
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Figure 4.2.Structures of the ornithine-containing degrons. (a) OWOWO (b) 
ScrOWOWO (c) III-67B (non-degron control peptide that is rapidily degraded in OPM2 
lysates).  Highlighted in blue are Orn residues sites which are sites to be modified by 
ubiquitination. 
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Figure 4.3.  Structures of OWOWO Arg-substituted degrons investigated for 
ubiquitination. (a) RWRWR (b) OWRWR (c) RWOWR (d) RWRWO.  Orn resides 
are highlighted in blue as sites modifiable by ubiquitination. 
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B. Results and discussion 
 
i. Ornithine ubiquitination in vitro 
 
 
Figure 4.4.Structure of OWOWO-RRRGproteasome reporter. Residues highlighted in 
blue are sites modified by ubiquitination.  
 
 
 The RRRG (Table 4.1) degron peptide, reported by Bonger et al. and further 
characterized by Melvin et al., has been shown to be a rapidily ubiquitinated substrate 
that adequately targets attached proteins to the proteasome within the cell.12,20  The 
RRRG degron (Sequence: RRRGGGGK) alone was sufficiently ubiquitinated, but was 
previously demonstrated to be susceptible to hydrolysis by cytosolic proteases.12 The 
OWOWOβ-hairpin protectide, which demonstrated substantial resistance to nonspecific 
proteases in vitro, was covalently attached to RRRG to protect the degron from 
degradation by proteases (Figure 4.4).  To determine the viability of the protected degron 
as a substrate for ubiquitination, the OWOWO-RRRG peptide was incubated in 
vitrowith HeLa S100 cytosolic lysates as the source of E1 activating enzyme, E2 
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conjugating enzyme, E3 protein ligase, as well as ATP-ERS (ATP energy regenerating 
solution), a DUB inhibitor (ubiquitin aldehyde), and methylated ubiquitin (MeUb) which 
prevents the formation of polyubiquitin chains due to methylation of all seven Ub Lys 
residue sidechains.21  The reactions were quenched at 4° C then subsequently incubated 
with control agarose beads prior to pull down (or immunoprecipitation) with agarose 
beads conjugated anti-ubiquitin antibodies to isolate only the ubiquitinated substrates 
(Tandem Ubiquitin Binding Entities or TUBEs, LifeSensors).22  The concentrated 
mixtures were then separated by gel electrophoresis and imaged using fluorescence 
detection (Typhoon Imager, GE LifeSciences at the Lineberger Cancer Institute) due the 
presence of the FAM fluorophore covalently attached to the β-hairpin peptides. Despite 
using MeUb, which cannot form polyubiquitin chains, the results revealed 
polyubiquitination and/or multi-monoubiquitination of the OWOWO-RRRG peptide, a 
degron with only one canonical modification site, a Lys residue at its C-terminus (Figure 
4.5, Table 4.1).21 We hypothesized that Orn, an analog of Lys, could serve as a 
ubiquitination site for the E3 ligases, resulting in multi-mono-ubiquitination of the 
peptide.   
_____________________ 
20Bonger, K.M.;  Chen, L.C.; Liu, C.W.; Wandless, T.J. Nat Chem Biol, 2011, 7, 531-7. 
21Houston, K.M.; Melvin, A.T.; Woss, G.S.; Waters, M.L.; Allbritton, N.L. Manuscript in 
preparation. 
 
22Hjerpe, R.; Aillet, F.; Lopitz-Otsoa, F.; Lang, V.; England, P.; Rodriguez, M.S. Eur Mol 
Biol Org2009, 10, 1250-58. 
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Figure 4.5 The ubiquitination of Orn residues by endogenous UPS enzymes from HeLa 
S100 lysates.  The OWOWO and OWOWO-RRRG degrons were incubated with HeLa 
S100 lysates in the presence of exogenous ubiquitin or methylate ubiquitin (MeUb). The 
modified degrons were isolated using TUBEs, were separated by gel electrophoresis and 
the results were determined by fluorescence imaging.21 
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To test this hypothesis, OWOWO without the degron was incubated with HeLa S100 
lysates with wild type ubiquitin or MeUb to evaluate substrate poly vs. multi-
monoubiquitination. Multi-ubiquitination was observed in both instances suggesting 
(Figure 4.5) that Orn does in fact serve as a ubiquitination site for modification by 
endogenous UPS enzymes, and that OWOWO can be ubiquitinated.  The results in lanes 
3 and 4 of Figure 4.5 suggest that OWOWO can be ubiquitinated at multiple sites since 
MeUb can not form polyubiquitin chains, though polyubiquitination of endogenous 
ubiquitin cannot ruled out. 
ii. Determination of the primary site of ornithine ubiquitination 
 
 To determine if there was a preferred ubiquitination site on the OWOWO 
peptide, several peptides were synthesized with all but one of the native Orn residues 
replaced with an Arg residue (Figure 4.3, Table 4.1).  The RWRWR peptide, where all 
of the Orn residues were substituted for Arg residues, served as a negative ubiquitination 
control.   Each of the Arg-substituted peptides, OWRWR, RWOWR, RWRWO, and 
RWRWR, as well as OWOWO were incubated with HeLa S100 lysates and either wild 
type ubiquitin or no Lys ubiquitin (No Lys Ub) where all of the ubiquitin Lys residues 
were mutated to Arg residues to prevent polyubiquitin chain.  Ubiquitin aldehyde, a 
potent DUB inhibitor, was also added to prevent deubiquitination of the modified 
reporters. The ubiquitin-modified degrons were isolated using TUBEs, separated by gel 
electrophoresis and imaged using fluorescence detection.  The OWOWO peptide 
displayed multi-ubiquitination in the presence of Ub as seen previously (Figure 4.5).  
Faint bands indicating multi-site ubiquitination were observed for OWOWO in the 
presence of No Lys ubiquitin but the majority of the peptide appeared to be mono-
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ubiquitinated (Figure 4.6).   The observation of predominantly mono-ubiquitinated 
peptide suggests that there is a primary site of modification and two minor modification 
sites though a small amount of peptide may have been polyubiquitinated by endogenous 
ubiquitin.  The results of the OWRWR, RWOWR, and RWRWO Ub-pull down assays 
demonstrated that the N-terminal Orn residue is the primary site of both mono-
ubiquitination and poly-ubiquitination (Figure 4.6).   This was not entirely surprising as 
N-terminal basic residues are a class of degrons according to the N-end rule proposed by 
Varshavsky.12   N-terminal basic residues present on proteins are more destabilizing, 
linked with intracellular lifetimes of approximately 2 minutes suggesting rapid turnover 
of such proteins by the proteasome.12   Faint bands indicative of tri-ubiquitinated product 
in the presence of No Lys ubiquitin could be due to polyubiquitination by endogenous 
ubiquitin. 
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Figure 4.6 Determination of the primary site of Orn ubiquitination on the OWOWO 
peptide.  The OWOWO, RWRWR, OWRWR, RWOWR, and RWRWO peptides 
were incubated in the presence of HeLa S100 lysates as a source of E1, E2, and E3 and 
exogenous ubiquitin or No Lys ubiquitin at 37° C.  Modified degrons were isolated by 
immunopreciptiation, separated by gel electrophoresis, imaged by fluorescence 
detection.21 
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iii. Secondary Structure Determination 
 
To determine whether or not the intrinsic structure of the OWOWO and OWRWR 
degron peptides affected the degree of ubiquitination, their secondary structure was 
characterized by circular dichroism (CD).  Additionally, a scrambled version of the 
OWOWO peptide, ScramOWOWO was synthesized and investigated by CD as well.  
The ScramOWOWO was designed to be a random coil peptide in order to determine 
whether or not secondary structure impacted the degree Orn ubiquitination.  The CD 
spectrum of the ScramOWOWO peptide suggests that it is unstructured based on the 
minima near 195 nm.  The CD spectrum of the OWOWO peptide displayed a β-hairpin 
conformation by the presence of minima near 205 nm and 215 nm (Figure 4.7).21 The 
maximum near 225 nm suggests that there are strong interactions between the indole 
rings of the cross-strand Trp residues.23   The OWRWR CD spectrum also illustrated β-
hairpin character with minima near 205 nm and 215 nm.  Exciton coupling between the 
sidechains of the cross-strand Trp residues was exhibited by the maximum near 225 nm.  
Though the CD spectra of OWOWO and OWRWR were nearly identical in terms of 
shape, there is a large difference in their mean residue ellipticities (MRE).   The 
minimum MRE of OWRWR is near 14,000 degcm2dmol-1 while the minimum MRE 
of the OWOWOβ-hairpin is near 26,000 degcm2dmol-1.  This suggested that 
OWOWO was more tightly folded than OWRWR.  This was not expected since Trp-
Arg diagonal pairs yield more tightly folded β-hairpins than Trp-Lys pairs, and Trp-Orn 
cation-π interactions are weaker than Trp-Lys cation-π interaction.24 
_________________________ 
23 Cochran, A.G.; Skelton, N.J.; Starovasnik, M.A. Proc Natl Acad Sci2001, 98, 5578-83. 
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Butterfield et al. reported 93% folding (determined by NMR) of a peptide very similar to 
RWRWR, which only differed by two amino acid residues. 24c Butterfield et al. also 
showed that the β-hairpin peptide with cross-strand Trp-Lys pair was 96% folded, 
slightly more tightly folded than the peptide with the cross-strand Trp-Arg pairs. The 
OWOWO and OWRWR peptides are similar to those reported by Butterfield et al. in 
that they have the potential for cross-strand cation-π and thus may behave differently 
than the β-hairpins with diagonal cation-π interactions reported previously.  Investigation 
by NMR would provide further information about degree of folding of the OWOWO and 
OWRWR β-hairpin peptides.  
 
 
________________________ 
24 (a)Tatko, C.D., Waters, M.L. Protein Sci, 2003, 12, 2443-2452. (b) 19Hughes, R.M.; 
Benshoff, M.L.; Waters, M.L. Chem-Eur J2007 13, 5753-64. (c) Butterfield,S.M.; 
Sweeney, M.M.; Waters, M.L.; J Org Chem2005, 70, 1105-14. 
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Figure 4.7  Circular dichroism spectra of the ScramOWOWO, OWOWO, 
OWRWR degron peptides.  Experiments were performed using 40 µM peptide in 10 
mM sodium phosphate buffer, pH 8 at 25°C. ScramOWOWO (blue) was found to be 
a random coil while OWOWO and OWRWR (green and purple respectively) both 
fold into a β-sheet conformation.21 
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vi.  Role of Secondary Structure 
 Several of the degrons used to investigate UPS activity, prior to this work, have 
been sequences derived from proteins that are natural substrates UPS in vivo.3,12  These 
short peptides, isolated from their full-length protein, were presumed to lack secondary 
structure or the secondary structure was ignored.  Here we investigate the role of 
secondary structure by qualitatively examining the difference in the degree of 
ubiquitination of the ScramOWOWO random coil peptide and the OWOWO and 
OWRWRβ-hairpin peptides.  The OWOWO and the ScramOWOWO have the same 
amino acids in their primary sequence, the same number of potential ubiquitination sites, 
but the amino acids are ordered differently resulting in a difference in secondary 
structure.  The peptides were incubated with OPM-2 cell lysates (multiple myeloma cell 
line), ubiquitin-aldehyde and added exogenous ubiquitin or No Lys ubiquitin, then 
isolated using a pull-down assay, and separated by gel electrophoresis.  The results 
shown in Figure 4.8 suggest that regardless of secondary structure, Orn is a substrate of 
ubiquitination.21  It is interesting to note that a preference of for the site of ubiquitination 
may differ depending on whether or not the degron peptide is inherently structured.  
Further investigation of this would involve mutating the Orn residues on the 
ScramOWOWO peptide individually to Arg residues to elucidate the primary site(s) of 
ubiquitination. 
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Figure 4.8  Determination of the significance of secondary structure in the ubiquitination 
of Orn residues.  OWOWO, OWRWR (β-hairpin peptides) and ScramOWOWO 
(random coil peptide) were incubated with OPM-2 lysates as a source of E1, E2, and E3 
enzymes and with exogenous ubiquitin or No Lys ubiquitin at 37° C. Modified degrons 
were isolated by immunopreciptiation, separated by gel electrophoresis, imaged by 
fluorescence detection.21 
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v. Resistance to proteolytic degradation in OPM-2 cell lysates 
 One of the major challenges in the development of peptide-based reporters of 
enzymatic activity is their susceptibility to hydrolysis by cytosolic peptidases.  We have 
shown that resistance to proteolysis can be conferred with a combination of secondary 
structure and the incorporation of noncanonical amino acids into the reporter primary 
amino acid sequence.  Previously we showed that OWOWO possessed an average half -
life of 315 minutes when incubated with nonspecific proteases in vitro (Chapter II, Figure 
2.9, Table 2.2).   A β-hairpin peptide with the same number of noncanonical amino acids 
as OWRWR had a half-life of 143 minutes under same conditions (Chapter II, Figure 
2.9, Table 2.2).    Since many of the proteases within cells are confined within 
membrane-bound organelles, we expected that β-hairpin peptides would be even more 
resilient in the cytosol of intact cells.25 
 The OWOWO, OWRWR, ScramOWOWO, and III-67B (positive control 
peptide) were incubated with OPM-2 whole cell lysates at 37° C and were quenched at 
various times between 0-120 minutes with 200 mM HCl.  The percentage of degron 
peptide hydrolysis by lysate proteases was determined using capillary electrophoresis 
with laser-induced fluorescence (CE-LIF). 
 The III-67B peptide is an Abl kinase reporter peptide whose degradations has 
been characterized in multiple cancer cell lines.19   The III-67B peptide is a 12-mer 
consisting of all canonical amino acids and presumably lacking secondary structure.  
________________________ 
25Belkhiri, A.; Lytvyn, V.; Guilbault, C.; Bourget, L.; Massie, B.; Nägler, D.K.; Ménard, 
R. Anal Biochem, 2002, 306, 237-46. 
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The lack of structure and canonical amino acids made it susceptible to proteolytic 
degradation by cytosolic peptidase.  In previous reports, the III-67B peptide was fully 
degraded by cytosolic proteases in 15 minutes.   We were unaware of any previous 
reports of characterizing the degradation of short peptides in OPM-2 cell lysates, thus III-
67B served two purposes: 1) to ensure that the OPM-cytosolic protease activity survived 
the cell lysis conditions and 2) to allow comparison of proteolytic activity in a multiple 
myeloma cell lysates with the protease activity of other cancer cell line lysates.19 We 
used this peptide as a control for the OPM-2 lysate degradation assay only.  The ability of 
the III-67B to serve as a substrate for the UPS machinery was not assessed in this study.    
 The III-67B peptide was fully degraded after 30 minutes in OPM-2 cell lysates, 
with a half-life of 6 minutes (Figure 4.9).  We are still optimizing the electrophoretic 
buffer conditions necessary to separate all of degradation fragments of the 
ScramOWOWO, OWRWR and the OWOWO peptides.  Thus the exact half-lives of 
these peptides in the presence of the proteases from OPM-2 cell lysates have not yet been 
determined though.   It is expected that the ScramOWOWO degron peptide, which lacks 
secondary structure, but has five noncanonical amino acids in its primary sequence, will 
be cleaved rapidly but not digested as rapidly as the III-67B peptide. Immune cell-
specific proteases such as tripeptidyl peptidase II (TPPII), though they are not presumed 
to be highly specific, have not evolved  to cleave after Orn or DPro residues which are not 
present in naturally occurring proteins.26 
________________________ 
26Tomkinson, B.; Lindas, A.C. Int J Biochem Cell Biol, 2005, 37, 1933-7 
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Given that trypsin, which specifically cleaves after basic amino acids, hydrolyzes Orn 
peptide bonds much less quickly than lysine amide bonds, the rates of hydrolysis by the 
aforementioned cytosolic proteases would likely be lower as well.27 We expect that the 
combination of secondary structure and noncanonical amino acids will result in increased 
resistance to degradation by cytosolic peptides.  Both OWRWR and OWOWO 
demonstrate significant secondary structure, thus we expect that these two β-hairpin 
peptides will be resistant to hydrolysis for longer than both the III-67B and the 
ScramOWOWO peptide.  However, the OWOWO peptide has more noncanonical 
amino acids than the OWRWR peptide and is therefore expected have the longest half-
life. Based on the long half-life of the OWOWO peptide in the presence of pronase E, it 
is possible that the OWOWO peptide will remain intact for the 2-hour duration of the 
OPM-2 lysate degradation assay.  We expect that the OWRWR and the OWOWO 
peptides will display a resiliency that will prove them suitable for single cell UPS activity 
analysis for long time periods. 
_________________________ 
27Seely, J.H.; Benoiton, N.L. Can J Biochem1970, 48, 1122-31. 
 
 
 
 
 
 
 
 
	   111	  
 
Figure 4.9 Electropherogram of III-67B peptide after degradation by proteolytic 
enzymes present in OPM-2 lysates as determined by CE-LIF.  Parent peptide (~100 
seconds) was fully degraded after 30 mins.  Parent peptide and degradation products were 
separated in 100 mM Tris, 100 mM Tricine buffer pH 8.1 at 15 kV for 600 seconds (10 
minutes) in a 30 µm capillary. 
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vi.  Investigation of possible acting E3 ligase 
 There are several commercially available inhibitors that specifically target E3 
ligases to modulate UPS activity within diseased cells.  A few of those inhibitors are in 
Phase I clinical trials (Serdemetan and Nutlin-3) while others are in clinical use 
(thalidomide).8  Though there are hundreds of E3 ligases in the cell, we were limited in 
our selection of potential targets due the narrow range of inhibitors to evaluate potential 
E3 ligases that facilitate the ubiquitination of OWRWR.  We chose to use OWRWR to 
allow us to elucidate any effect of the E3 ligase inhibitors on polyubiquitination. 
OWRWR was incubated in the presence of HeLa S100 lysates, exogenous ubiquitin, and 
one of six E3 ligase inhibitors (Serdemetan28a, Nutlin-328b, Skpin C128c, SMER328d, 
TAME HCl28e, and thalidomide10,28f) shown in Figure 4.10, as well as with ubiquitin 
aldehyde, a DUB inhibitor, to prevent the deubiquitination of the peptide.290 
_________________________________ 
28(a)Kojima, K.; Burks, J.K.; Arts, J.; Andreef, M. Mol Cancer Ther, 2010, 9, 2545-57. 
(b) Vassilev, L.T; Vu, B.T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, 
N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E.A. Science, 2004, 303, 844-
8. (c) Wu, L.; Grigoryan, A.V.; Li, Y.; Hao, B.; Pagano, M.; Cardozo, T.J.  Chem Biol, 
2012, 19, 1515-24. (d) Aghajan, A.; Jonai, N.; Flick, K.; Fu, F.; Luo, M.; Cai, X.; Ouni, 
I.; Pierce, N.; Tang, X.; Lomenick, B;, Damoiseaux, R.; Hao, R.; Del Moral, P.M.; 
Verma, R., Li, Y., Li, C., Houk, K.N., Jung, M.E., Zheng, N., Huang, L., Deshaies, R.J., 
Kaiser, P.; Huang, J.  Nat Biotechnol, 2010, 28, 738-42. (e) Zeng, X.; Sigoillot, F.; Gaur, 
S.; Choi, S.; Pfaff, K.L.; Oh, D.C.; Hathaway, N.; Dimova, N.; Cuny, G.D.; King, R.W. 
Cancer Cell, 2010, 18, 382-95. (f) Ito, T.;Ando, H.; Suzuki, T.; Ogura,T.; Hotta, K.; 
Imamura, Y.; Yamaguchi, Y.; Handa, H. Science, 2010, 327, 1345-50. 
 
29Hershko, A.; Rose, I.A., Proc Natl Acad Sci USA, 1987, 84, 1829-33. 
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The reactions were quenched, isolated, and detected using the Ub-pull-down assay 
described earlier.   An E1 activating enzyme inhibitor, PYR-41, was incubated with 
OWRWR as a negative control and DMSO was added to one reaction mixture instead of 
an inhibitor to serve as a positive ubiquitination control.30 The results are shown in Figure 
4.11.  There is less ubiquitination observed in the presence of PYR-41 than in the 
presence of DMSO, but there is still some modification of OWRWR seen, suggesting 
that the PYR-41 did not fully inhibit ubiquitination.  PYR-41 is not a global E1 inhibitor 
though it dramatically reduced ubiquitination activation HeLa cells at 50 µM inhibitor 
concentration.  Our assay was done at 30 µM inhibitor concentration (three times the 
IC50) thus increasing the inhibitor concentrations may remedy the problem.  There could 
have been E1 enzymes present in the lysate already loaded with endogenous ubiquitin, 
although this concentration was expected to be small.  OWRWR ubiquitination was seen 
in the presence of all the E3 ligase inhibitors though polyubiquitin chain formation was 
greatly reduced in the presence of SMER3, TAME HCl and thalidomide (Figure 4.11, 
Lanes 4, 5, 6).  These experiments were all performed, in triplicate, at inhibitor 
concentrations three times that of the IC50 value for all the enzymes. Experiments are 
currently underway at five times the IC50 to confirm these findings. 
________________________ 
30Yang, Y.; Kitagaki, J.; Dai, R.M.; Tsai, Y.C.,;Lorick, K.L.;Ludwig, R.L.; Pierre, S. 
A.,;Jensen, J.P.; Davydov, I.V.; Oberoi, P.;Li, C.C.H.; Kenton, J.H.; Beutler, J.A.,; 
Vousden, K. H.; Weissman, A.M. Cancer Res, 2007, 67, 9472-81 
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Figure 4.10  Structures of E3 ligase inhibitors and of an E1 conjugating enzyme inhibitor 
used in the ubiquitination pull-down assay. a) Serdemetan (HDM2 inhibitor) b) Nutlin-3 
(MDM2 inhibitor) c) Skpin C1 (SCF-Skp2 inhibitor)d) SMER3 (SCFMet30 inhibitor) e) 
TAME HCl  (APC/C inhibitor) f) Thalidomide (Cereblon-DDB1-Cul4A complex 
inhibitor) g) PYR-41 (E1 inhibitor).10,21,28 
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Figure 4.11. E3 Ligase Inhibitor Assay.  The OWRWR peptide (10 µM) was incubated 
with HeLa S100 lysates (2 mg/mL) and in the presence of E3 ligase inhibitors (30 µM 
serdementan, 0.27 µM nutlin-3, 150 µM SKPin C1, 300 µM SMER3, 600 µM TAME, 90 
µM thalidomide,or 30 µM PYR-41) for 2-8 hours.  Ubiquitinated OWRWR peptide was 
isolated and separated by gel electrophoresis and analyzed by fluorescence imaging.21 
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vii. Cell permeability of Orn-degrons 
 
 Measuring cellular ubiquitin-mediated proteasomal activity in patient samples ex 
vivo must be done using a method that is amenable to small sample sizes of less than one 
thousand diseased cells.  Assays utilizing cell lysates and/or antibody detection generally 
require one million cells or greater to surpass detection limits.  An easily detected, cell 
permeable UPS activity reporter, coupled with sensitive instrumentation, would be ideal 
for such an application.  Arginine-rich peptides, such as the TAT sequence, are known to 
be cell permeable and are generally believed to be endocytosed by HeLa cells.31  It was 
expected that our highly positively charged degron peptides would be cell permeable in 
HeLa cells as well.   Fluorescence microscopy of positively charged β-hairpin peptides 
incubated with HeLa cells revealed membrane permeability of the peptides but the 
observance of punctate domains implied endosomal entrapment (data not shown). 
Though cell permeability is a necessary feature of our degron peptides to be used in 
assays with small patient sample sizes, endosomal entrapment of the degrons would 
prevent ubiquitination and detection of modified or degraded reporter.   OPM-2 cells 
however may have little or no transmembrane trafficking by endocytotic mechanisms.  
Cell permeable Orn-degron reporter peptides that can penetrate OPM-2 cells by direct 
penetration could serve as model systems for optimizing the detection of UPS activity in 
multiple myeloma patient cells using single cell CE-LIF. 
________________________ 
31Zhang, X.; Jin, Y., Plummer, M.R.; Pooyan, S.;  Gunaseelan, S.; Sinko, P.J. Mol 
Pharm, 2009, 3, 836-48. 
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To determine the cell-permeability of the Orn-degron β-hairpins OWRWR and 
OWOWO in OPM-2 cells, each peptide was incubated with OPM-2 cells at different cell 
densities for 2-4 hours at 37°C.  After incubation, the cells were trypsinized to digest any 
peptide that was present in the extracellular space and on the outside of the cell 
membranes, and then washed to removed the digested fragments.  The cells were then 
imaged using fluorescence microscopy.  No fluorescence was seen inside the cells (data 
not shown) indicating that OPM-2 peptides were not significantly cell permeable (data 
not shown).    
viii. Ex vivo ubiquitination of OWOWO degron peptide 
 The poor membrane permeability of the OWOWO prevented the detection of 
intracellular ubiquitination ex vivo by simply incubating the peptide with the cells 
unassisted.  Other methods for peptide cell permeation include microinjection (of single 
cells), electroporation, or pinocytosis.   Microinjection has been used previously for the 
beta-bend protectides used as kinase reporters.32  We chose electroporation because we 
already had the necessary equipment and reagents.  Electroporation of cells is the 
induction of transient pore formation within the cell plasma membrane by the an applied 
electric field.33  OPM-2 cells (5 x 105-2 x 106 per well) were electroporated with 10 µM 
or 25 µM OWOWO and then allowed to recover at 37° C for 4 hours.  We also added a 
DUB inhibitor (PR-619) and a proteasome inhibitor (MG-132) to prevent the 
deubiquitination or degradation of the OWOWO degron peptide.  The cells were then 
lysed and the degree of ubiquitination of the OWOWO degron peptide was determined 
using gel electrophoresis and fluorescence detection (Figure 4.12).   
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No ubiquitination of OWOWO was observed.  It is important to note that in previous 
assays, exogenous ubiquitin was added and the lysates were incubated with ubiquitin 
antibodies conjugated to beads to isolate modified reporter only, thus enhancing the 
signal.  No such measures were taken with the ex vivo cellular assay.  Before repeating 
the assay and following up with a Ub-pull-down assay, we wanted to ensure that the 
OWOWO peptide was being sufficiently loaded using electroporation.  The OPM-2 cells 
were electroporated with 10 µM or 25 µM OWOWO peptide and allowed to recovery at 
37°C for 30 minutes.  The cells were then imaged using fluorescence microscopy (Figure 
4.12).  Using the most optimal protocol, OWOWO appeared to be loaded into the OPM-
2 cells though the loading efficiency was not determined.  Few cells showed uniformly 
dispersed fluorescence, while the majority of cells containing fluorescent degron peptide 
displayed punctate domains of fluorescence characteristic of endosomal entrapment.34 
The lack of detection of ubiquitinated peptide in the ex vivo cellular assay may have been 
due to inefficient loading of the OWOWO peptide degron or its localization within 
endosomes.  Despite many attempts to optimize the electroporation protocol, punctate 
domains were repeatedly observed by fluorescence microscopy.  
__________________________ 
32Yang,S.; Proctor, A., Cline, L.L.; Houston, K.M.; Waters, M.L., Allbritton, N.L. 
Analyst, 2013, 138, 4305-11. 
 
33Glogauer, M.; Lee, W.; McCulloch, C.A.G. Exp Cell Res, 1993, 208, 232-40. 
 
34Richard, J.P.; Melikov, K.; Vives, E.; Ramos, C.; Verbeure, B.; Gait, 
M.J.;Chernomodik, L.V.; Lebleu, B. J Biol Chem, 2003, 278, 585-90. 
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Figure 4.12  Electroporation of OPM-2 cells for the membrane permeation of the 
OWOWO degron peptide imaged by fluorescence microscopy.  10 µM OWOWO 
peptide was used with a cell density of 1.5 x107.  BF represents bright field images of the 
cells.  FAM represents cells imaged by fluorescence detection.  X-005 was the 
electroporation preset protocol optimized for U266B1 (lyphoblast plasmacytoma, 
myeloma) cells.  W-001 was the preset protocol for U-937 (human histiocytic lymphoma) 
cells.   
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The lack of detection of modified OWOWO in the ex vivo cellular assay could have 
been due to many impeding factors.  Unaided, OWOWO may not be able to penetrate 
OPM-2 plasma membranes efficiently.  With the assistance of electroporation, OWOWO 
is loaded into OPM-2 cells but may be trapped in endosomes.  Sufficient amounts of the 
OWOWO peptide need to be free within the cytosol, where the UPS machinery is 
located, to be modified and detected.  Though electroporation greatly enhances cellular 
uptake of otherwise blocked exogenous molecules, electroporation is also associated with 
increased uptake by endocytosis.34   It is possible that the majority of the OWOWO 
loaded into the OPM-2 cells was present in endosomes and thus unavailable to serve as a 
substrate for the UPS machinery in the cytosol.     
 Another factor to take into consideration is how well OWOWO can compete with 
endogenous substrates of UPS machinery.   Though we have shown that ornithine can be 
ubiquitinated, the rate and catalytic efficiency of ornithine ubiquitination may be lower 
than that of lysine ubiquitination.  Intracellular concentrations of ubiquitin may be too 
low to modify OWOWO enough to be observed by gel electrophoresis-fluorescence 
detection.  Currently work is being done in the Allbritton Group in collaboration with the 
Waters Group to detect ubiquitination of OWRWR degron peptide using CE-LIF. 
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D. Conclusions  
 We have successfully synthesized and characterized novel degron peptides that 
adequately served as reporters of UPS activity in vitro.  We identified the noncanonical 
amino acid ornithine as substrate for endogenous UPS proteins in HeLa cell lysates 
(cervical cancer cell line) and OPM-2 cell lysates (multiple myeloma cell line) regardless 
of degron peptide secondary structure.   We observed poly-ubiquitin chain formation on 
the OWRWR degron peptide, however the type of linkage (K48 or K63 linked, branched 
or linear, etc) was not determined.   The unstructured and structured orn-degron peptides 
are expected to show greater resistance to proteolysis by OPM-2 cell lysates than the all-
canonical amino acid control peptide.  With the continued identification of new E3 
ligases (currently >600 known E3s), it is likely that Orn-degron peptides are nonspecific 
reporters of UPS activity and can be modified by multiple families of E3 ligases.  
Nonetheless, we demonstrated that the addition of certain E3 ligase inhibitors, namely, 
SMER3, TAME HCl and Thalidomide, prevent poly-Ub chain formation of OWRWR 
though mono-Ub was seen in the presence of all inhibitors.   While this data did not 
indicate the specificity of our peptide reporter, it does show the potential of the 
OWRWR to be used to determine the effect of thalidomide, SMER-3 and TAME-HCl 
treatment on patient UPS activity.  It would be interesting to determine if there is a 
difference in ubiquitination of the OWRWR peptide in cell lysates treated with both a 
proteasome inhibitor and an E3 ligase inhibitor such as thalidomide which is commonly 
used in addition to proteasome inhibitors to treat multiple myeloma patients.  Further 
optimization is required however before the OWRWR or OWOWO degron peptides can 
be used as cellular UPS activity reporters ex vivo.  Inherent OPM-2 cell permeability of 
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the OWOWO and OWRWR degron peptides was not detected by fluorescence 
microscopy, meaning use in single patient cells would require microinjection or further 
modification to induce cell permeability.  The OWOWO peptide was successfully loaded 
into OPM-2 cells by electroporation but the majority of the peptide was likely trapped in 
endosomes.  The concentration of OWOWO that was freely diffusing in the cytosols of 
intact OPM-2 cells was not sufficient enough to compete with endogenous substrates of 
the UPS proteins to be modified at detectable levels for analysis by gel electrophoresis-
fluorescence detection.   Given that ornithine ubiquitination may be slower and less 
efficient than lysine ubiquitination, higher concentrations of reporter effectively loaded 
non-endosomally may remedy the lack of modified reporter detection.  The use of 
ornithine in peptide-based reporters of UPS activity is still valuable as it confers protease 
resistance allowing detection of UPS activity for extended periods of time in the absence 
of protease inhibitors. 
E. Ongoing work  
 Currently, the Allbritton Group in collaboration with the Waters Group is 
evaluating ubiquitination of the OWRWR degron peptide in other cancer cell lines using 
CE-LIF.   The sensitivity of CE-LIF allows for lower limits of detection and the use of 
fewer cells in the analysis of detection of UPS activity in whole single cells and cell 
lysates assays.  Eventually further modification will be done to promote non-endocytotic 
cell permeability of OWRWR.   
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F. Experimental 
Peptide Synthesis and Purification 
Peptides were synthesized using manual or automated standard solid phase peptide 
synthesis (Thuramed Peptide Synthesizer, CEM Liberty1 Microwave Peptide 
Synthesizer) using Fmoc protected amino acids on 0.06 mmol of CLEAR Amide resin 
from Peptide International.   Four equivalents of standard amino acids were used each 
peptide synthesis while 2 equivalents of noncanonical amino acids and fluorophores were 
used.  All peptides were acetylated at the N-terminus by treating the resin with 5% acetic 
anhydride and 6% 2,6-lutidine in 5 mL of DMF bubbling with N2 for 40 minutes.  5(6)-
Carboxyfluorescein or 6-carboxyfluorescein (FAM) was coupled to the εNH of lysine or 
the δNH of ornithine in i+4 position of the beta-hairpins or the centrally located amino 
acids of the scrambled sequences.  The sidechains of these amino acids were orthogonally 
protected with an allyloxycarbonyl group (N-Aloc) or with 1-(4,4-dimethyl-2,6-
dioxocyclohex-1-ylidene-3-methylbutyl (N-ivDde).   Aloc removal done based on the 
protocol published by Pazos et al.35 The removal of  ivDde from the sidechain of lysine 
or ornithine was accomplished by treating the peptide resin three times with 20 mL of 2% 
hydrazine monohydrate in DMF bubbling with N2 for two minutes each time followed by 
washing with DMF, MeOH, DCM.   Following deprotection, FAM was coupled using 2 
equivalents of FAM, 5 equivalents of PyBOP/HOBt and 8 equivalents of DIPEA in 5 mL 
of DMF and allowed to bubble with N2 for 4-8 hours.  Double coupling was sometimes 
required.   
_______________________ 
35Pazos, E.; Jiménez-Balsa, A.; Maszareñas, J.L.;  Vázquez, M.E. Chem Sci2011, 2, 
1984-87 
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Kaiser testing was done after the capping, deprotection and coupling steps.  Peptides 
without cysteine were cleaved from the resin in 9.5:2.5:2.5 trifluoroacetic acid (TFA), 
TIPS and water respectively for 3-4 hours. Peptides containing cysteine were cleaved 
using 9.4:2.5:2.5:1 trifluoroacetic acid (TFA), EDT, water and TIPS respectively for 3-4 
hours. The TFA was evaporated and the cleaved peptides were precipitated using cold 
ethyl ether and extracted with water.  Extracted peptides were lyophilized and then 
purified using RP-HPLC on a Vydac C18 semi-preparative column with a gradient from 
‘0 to 100% B’ in 45-120 minutes.  Solvent A was 95% water, 5% acetonitrile and 0.1% 
TFA and Solvent B was made of 95% acetonitrile, 5% water and 0.1% TFA.  Purified 
peptides were lyophilized and their synthesis and purity confirmed by ESI-TOF or 
MALDI-TOF using dihydroxybenzoic acid matrix. 
 
Peptide Concentration Determination. 
 
UV/Vis was used for the concentration determination of each peptide in 10 mM sodium 
phosphate buffer (100 mM NaCl, pH 7.48 for protease degradation studies) pH 8 using 
FAM abosorbance at 492 nm, ε492 = 78,000 M-1 cm-1 for peptides with FAM or through 
6M Guanidine hydrochloride denaturation and tryptophan absorbance at 280 nm ε280 = 
5690 M-1cm-1  for those peptides without FAM. 
 
CD Spectroscopy  
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CD spectroscopy data was collected using an Applied Photophysics Chiroscan Circular 
Dicroism  Spectrophotometer.  Spectra were generated at 25 °C with a wavelength scan 
260 nm to 185 nm, with 0.5 second scanning in a 0.1 cm cell.  Peptide concentrations of 
40 µM in 10 mM sodium phosphate buffer, pH 8.02 (peptides with FAM) or pH 7.42 
(peptides without FAM) were used. 
 
Cell culture and lysate generation 
 
HeLa S3 cells (ATCC) were maintained in Dulbecco’s modified eagle medium (DMEM) 
with 10% v/v bovine calf serum (HyClone) and maintained in a 37°C, 5% CO2 
environment.  OPM-2 cells (a kind gift from Donald McDonnell) were maintained in 
RPMI 1640 media supplemented with 12% fetal bovine serum (HyClone), 21.8 mM 
glucose, 8.6 mM HEPES (pH 7.4) and 1.0 mM sodium pyruvate.  All media components 
are from Cellgro unless otherwise noted.  Unless otherwise noted all reagents used in 
following assays are from Sigma-Aldrich.  HeLa S100 cytosolic lysates were generated 
from cells based on the Dignam protocol as previously described.1 Isolated HeLa S100 
cytosolic lysates were then quantified with a Nanodrop 2000 (Thermo Scientific), 
aliquoted, and stored at -80°C.  To generate lysates from OPM-2 cells, ~2.4x 107 cells 
were washed twice with 1X PBS and then resuspended in 200 µL of 1X PBS. Cells were 
submerged in liquid nitrogen for 1 min and immediately thawed in a 37° C water bath.  
The freeze-thaw cycle was repeated 3-5 times (a total of 4-6 cycles) followed by 
centrifugation at 14,000 rcf at 4° C for 15 min.  The supernatant was removed and kept at 
4° C for the duration of the experiment and the pellet was discarded.  Lysates were used 
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within 4 h of generation.  Total protein concentration of the OPM-2 lysate was 
determined by mixing 30 µL of lysate (diluted 1:1000 in 1X PBS) with 10 µL of 
fluorescamine (3 mg/mL) followed by a 5 min incubation in the dark at room 
temperature. Fluorescence was measured with a M5 Molecular Devices Spectrometer 
(475 nm) and compared with a BSA/fluorescamine protein standard for quantitation 
purposes. 
 
Measurement of Degron Peptide Degradation in OPM-2 Cell Lysate.   
 
OPM-2 cells cultured in six T-75 culture flasks (with an approximate cell density of  4 x 
106 celss/flask) combined centrifuged at 0.8 rcf for 2.5 minutes.  Media was discarded the 
cells were washed twice with 10 ml of  1X PBS (137 mM NaCl, 27 mM KCl, 10 mM 
Na2HP04, 1.75 mM KH2PO4, pH 7.4).  Supernatant was discarded and the combined 
pellet was resuspended in 200 µL of 1X PBS.  Cells were submerged in liquid nitrogen 
for 1 min and immediately thawed in a 37° C water bath.  The freeze-thaw cycle was 
repeated 3-5 times (a total of 4-6 cycles).  Cells were centrifuged at 14,000 rpm at 4° C 
for 15 minutes.  The supernatant was removed and kept at 4° C for the duration of the 
experiment.  The pellet was discarded.  Lysates were used within 4 hours of generation. 
Total protein concentration in the OPM-2 lysate was determined by mixing 30 µL of 
lysate (diluted 1:1000 in PBS) with 10 µL of fluorescamine (3 mg/mL) and allowing 
them to react for 5 minutes at room temperature in the dark.  Immediately after, the 
fluorescence was measured using M5 Molecular Devices Spectrometer (475 nm) and 
compared with that of BSA protein standards mixed with fluorescamine.  A 200- 400 µL 
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solution was made containing 3 mg/mL final OPM-2 lysate concentration and 10 uM 
final peptide concentration.  The peptide/lysate solutions were incubated at 37 °C and 
aliquots of 20-40 µL were removed at various times points (1, 3, 5, 10, 15, 30, 60, 90, 
120 minutes) and quenched with equal amounts of 200 mM HCl.  Aliquots were frozen 
and stored at -20° C until time of analysis. 
 
Capillary Electrophoresis 
 
Detection of peptide degradation in OPM-2 lyastes was achieved by laser-induced 
detection (LIF, 488 nm) during capillary electrophoresis(ProteomeLab PA800, Beckman 
Coulter, Fullerton, CA).  Fused-silica capillaries (30 or µm 50 µm inner diameter, 360 
µm outer diameter, Polymicro Technologies, Phoenix, Az) were used with an effective 
length of 20 cm and a total length of 30 cm. Capillaries were preconditioned with 1 
NaOH for 12 h, DI H2O for 1 h, 0.1 M HCl for 6 h followed by DI H2O for 12 h.  
Between each sample run, a pressure of 20 psi was applied at the capillary inlet allowing 
the capillaries to be rinsed with 1 NaOH for 2 min, DI H2O for 2 min, and with 
electrophoretic buffer for 2 min.  Quenched samples from the OPM-2 lysate degradation 
assay were diluted in 100 mM Sodium Phosphate Buffer (4 µL sample in 196 µL of 
buffer).    Several electrophoresis buffers were tested.  Initially quenched samples were 
diluted 1:100 in sample buffers that were identical to the electrophoretic buffers.  As 
more electrophoretic buffers were tested to determine optimal separation conditions, 4 µL 
of each sample was diluted in 196 uL of 100 mM sodium phosphate buffer, pH 8.3, 
regardless of the electrophoretic buffer.  The electrophoretic buffers tested include, 100 
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mM Tris, 100 mM Tricine Buffer pH 8. 1, 400 µM sodium phosphate buffer, pH 7.3, 10 
mM sodium phosphate buffer, pH 8. 3, (30 µm capillary), 100 mM sodium phosphate 
buffer, pH 8.3, 200 mM sodium phosphate buffer, pH 8.3, 300 mM sodium phosphate 
buffer, pH 8.3, 400 mM sodium phosphate buffer, pH 8.3, 500 mM sodium phosphate 
buffer pH 7.3, 150 mM sodium phosphate buffer, 1 mM sodium deoxycholate (SDC), pH 
7.3, 150 mM sodium phosphate buffer, 2 mM sodium deoxycholate (SDC), pH 7.3, 150 
mM sodium phosphate buffer, 3 mM sodium deoxycholate (SDC), pH 7.3, 150 mM 
sodium phosphate buffer, 4 mM sodium deoxycholate (SDC), pH 7.3, 150 mM sodium 
phosphate buffer, 5 mM sodium deoxycholate (SDC), pH 7.3, 300 mM sodium phosphate 
buffer, 1 mM sodium deoxycholate (SDC), pH 7.3, 300 mM sodium phosphate buffer, 2 
mM sodium deoxycholate (SDC), pH 7.3, 300 mM sodium phosphate buffer, 3 mM 
sodium deoxycholate (SDC), pH 7.3, 300 mM sodium phosphate buffer, 4 mM sodium 
deoxycholate (SDC), pH 7.3 (50 µm capillary).  Sample was loaded into the capillary 
hydrodynamically by applying a pressure of 0.5 psi at the inlet for 5 sec.  A negative 
voltage was then applied to initiate electrophoresis.  Electrophoresis was done for 10 
mins with a field strength of 8 kV cm-1 (Tris-Tricine buffer), 30 mins with a field strength 
of 8 kV cm-1  (sodium phosphate buffers), or for 60 mins with a field strength of 8 kV 
cm-1  (sodium phosphate buffers during OWRWR sample separations).   Results were 
analyzed using 32 Karat, version 8.0 (Beckman Coulter, Fullerman, CA).  
 
Ubiquitin pull down assay 
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The ubiquitin pull down assay was carried out at the indicated times at 37° C in a total 
reaction volume of 100 µL containing assay buffer (10 mM Tris-HCl pH 7.6 and 5 mM 
MgCl2) with 2 mM DTT, 20 µg/mL ubiquitin aldehyde (Boston Biochem), 400 µg/mL 
ubiquitin or no Lys ubiquitin (Boston Biochem), 1X ATP energy regenerating solution 
(ATP-ERS, Boston Biochem), and 4.2 µg of indicated peptide substrate or 10 µM 
OWRWR degron peptide (E 3 Ligase inhibitor assay).  Either 2 mg/mL HeLa S100 
cytosolic lysates or 3.2 mg/mL OPM-2 lysates were used as the source of E1, E2, and E3 
enzymes. Single inhibitory compounds (all obtained from LifeSensors) were added to the 
assay at the following concentrations for the duration of the assay: 30 µM serdementan, 
0.27 µM nutlin-3, 150 µM SKPin C1, 300 µM SMER3, 600 µM TAME, 90 µM 
thalidomide,or 30 µM PYR-41. At the end of the indicated times, samples were incubated 
with Control-Agarose beads (LifeSensors), diluted in TBS-T buffer (20 mM Tris-HCl pH 
8.0, 150 mM NaCl, and 0.1% v/v Tween-20), for 60 min on a tube rotator at 4°C.  
Samples were subsequently centrifuged at 1800xg for 5 min to pellet and remove control 
beads.  The supernatant was transferred to a solution of Agarose-TUBEs (LifeSensors) 
diluted in TBS-T and incubated overnight on a tube rotator at 4° C.  Ubiquitin-bound 
beads were washed 5X with TBS-T and then the samples were eluted off of the bead with 
2X tricine sample buffer, heated for 5 min (>90° C), and then isolated by centrifugation 
for 5 min at 13000xg.  Samples were loaded onto SDS page gels (precast 16.5% Mini 
PROTEAN Tris-Tricine, Bio-Rad) using 1X tris-tricine running buffer (80 minutes at 120 
V) and visualized with a Typhoon Imager 9400 at 600-1000 PMT (GE Healthcare Life 
Sciences).  Gels were quantified using ImageJ (US National Institute of Health) by 
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comparing sample intensity to unreacted parent peptide intensity, which is not depicted in 
the gels.   
 
Electroporation 
 
All electroporation of OPM-2 cells was done using a Nucleofector™ manufactured by 
Lonza.  Protocols A-030 (T2 cell line), T-005 (NSO cell line), W-001 (U-937) , X-001 
CCRF-CEM cell line), and  X-005 (U266B1 cell line) were tried using solution kit C 
were followed according to the instructions published on the Lonza website. Recovery 
times were 15 mins-4 h.  Cell count was between 1-10 x107. 
 
Fluorescence Microscopy 
 
Post-electroporation cells were allowed to recover in OPM-2 complete media for 15 min-
4 h at 37°C in 5% CO2.  Cells were then washed 3X with 1 X PBS and resuspended in 
extracellular buffer, pH 7.4.  Cells were imaged at room temperature on plastic coverslips 
incased by rubber o-rings without being immobilized by Cell Tak™.  Bright field images 
were taken with a 3 ms exposure time while fluorescence imaging was done using a GFP 
filter with 100 ms, 500 ms, and/or 1000 ms exposures.   
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